

Set Items Description

 ? e au=morei n, br or ?

Ref	Items	Index-term
E1	2	AU=MOREI N, B*
E2	118	AU=MOREI N, BROR
E3	0	*AU=MOREI N, BROR?
E4	6	AU=MOREI N, C.
E5	4	AU=MOREI N, CHRI STI NE
E6	2	AU=MOREI N, G
E7	6	AU=MOREI N, G
E8	5	AU=MOREI N, GLEB
E9	1	AU=MOREI N, GLEB YUREVI CH
E10	1	AU=MOREI N, H. L.
E11	1	AU=MOREI N, J
E12	2	AU=MOREI N, J.

Enter P or PAGE for more
 ? s e1-e3

	2	AU=MOREI N, B*
	118	AU=MOREI N, BROR
	0	AU=MOREI N, BROR?
S1	120	E1- E3
? s s1 and qui l ?	120	S1
	25651	QUI L?
S2	16	S1 AND QUI L?

? rd

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S3 16 RD (unique items)

? t s3/3, k/1-16

>>>KW C option is not available in file(s): 399

3/3, K/1 (Item 1 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

149017707 CA: 149(1)17707d PATENT

Use of lipid containing particles such as liposomes, iscom and/or iscom matrix and posintros, comprising Quillaja saponins, for the treatment of cancer

INVENTOR(AUTHOR): Hu, Kefei; Morein, Bror

LOCATION: Swed.

ASSIGNEE: Duecom

PATENT: PCT International ; WO 200863129 A1 DATE: 20080529

APPLICATI ON: WO 2007SE50878 (20071120) *US 2006PV866445 (20061120)

PAGES: 86pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFI CATIONS:

I PCR/8 + Level Value Position Status Version Action Source Office:

A61K-0031/704 A I F B 20060101 H SE

A61K-0039/39 A I L B 20060101 H SE

A61P-0035/00 A I L B 20060101 H SE

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY;

10562866.txt

MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

3/3, K/2 (Item 2 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

142259614 CA: 142(14)259614u JOURNAL

The immunomodulating properties of human respiratory syncytial virus and immunostimulating complexes containing Quillaja saponin components QH-A, QH-C and ISCOPREP703

AUTHOR(S): Hu, Ke-Fei; Regner, Matthias; Siegrist, Claire-Anne; Lambert, Paul; Chen, Margaret; Bengtsson, Karin Loevgren; Mörén, Bror

LOCATION: Biomedical Center, Section of Virology, Department of Veterinary Microbiology, Swedish University of Agricultural Science, S-751 23, Uppsala, Swed.

JOURNAL: FEMS Immunol. Med. Microbiol. (FEMS Immunology and Medical Microbiology) DATE: 2005 VOLUME: 43 NUMBER: 2 PAGES: 269-276 CODEN: FIMEV ISSN: 0928-8244 PUBLISHER ITEM IDENTIFIER: 0928-8244(04)00189-0 LANGUAGE: English PUBLISHER: Elsevier B.V.

3/3, K/3 (Item 3 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

142133049 CA: 142(8)133049v PATENT

Quil A fraction with low toxicity for adjuvant application

INVENTOR(AUTHOR): Mörén, Bror; Loevgren Bengtsson, Karin; Ekstroem Jill; Ramlund, Katarina

LOCATION: Swed.

ASSIGNEE: Isconova AB

PATENT: PCT International ; WO 200502620 A1 DATE: 20050113

APPLICATION: WO 2004SE1038 (20040707) *SE 20031998 (20030707)

PAGES: 62 pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-039/39A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

3/3, K/4 (Item 4 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

142021880 CA: 142(2)21880c JOURNAL

Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunization against respiratory syncytial virus infection

AUTHOR(S): Regner, Matthias; Cullley, Fiona; Fontannaz, Paola; Hu, Kefei;
Page 2

10562866.txt

Mbrein, Bror; Lambert, Paul-Henri; Openshaw, Peter; Siegrist, Claire-Anne
LOCATION: CMU, Departments of Pathology and Paediatrics, WHO
Collaborating Center for Vaccinology, University of Geneva, 1211 4, Geneva,
Switz.
JOURNAL: Microbes Infect. (Microbes and Infection) DATE: 2004 VOLUME: 6
NUMBER: 7 PAGES: 666-675 CODEN: MICNFS ISSN: 1286-4579
PUBLISHER ITEM IDENTIFIER: 1286-4579(04)00102-9 LANGUAGE: English
PUBLISHER: Elsevier Science B.V.

3/3, K/5 (Item 5 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rights reserved.

141312939 CA: 141(19)312939m PATENT
Vaccine compositions comprising ISCOM particles and killed or inactivated
live microorganisms or antigen molecules
INVENTOR(AUTHOR): Mbrein, Bror; Loevgren Bengtsson, Karin
LOCATION: Swed.
ASSIGNEE: Isconova AB
PATENT: PCT International ; WO 200484941 A1 DATE: 20041007
APPLICATION: WO 2004SE451 (20040324) *SE 2003795 (20030324)
PAGES: 30 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/39A; A61K-039/00B
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
SD; SL; SZ; TZ; UG; ZM; ZW AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT; BE;
BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PL;
PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE;
SN; TD; TG

3/3, K/6 (Item 6 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rights reserved.

140092573 CA: 140(7)92573z PATENT
ISCOM preparations for production of monoclonal antibodies and as
adjuvant to vaccines
INVENTOR(AUTHOR): Mbrein, Bror; Loevgren Bengtsson, Karin
LOCATION: Swed.
ASSIGNEE: Isconova AB
PATENT: PCT International ; WO 200404762 A1 DATE: 20040115
APPLICATION: WO 2003SE1180 (20030707) *SE 20022110 (20020705)
PAGES: 38 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/39A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU;
SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN;
YU; ZA; ZM; ZW AM; AZ; BY; KG; KZ; MD; RU DESIGNATED REGIONAL: GH; GM; KE;
LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW AT; BE; BG; CH; CY; CZ; DE; DK;
EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL; PT; RO; SE; SI; SK; TR; BF;
BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

3/3, K/7 (Item 7 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

128087569 CA: 128(8)87569a JOURNAL

Effects of carbohydrate modification of Quillaja saponaria Molina QH-B fraction on adjuvant activity, cholesterol-binding capacity and toxicity

AUTHOR(S): Ronnberg, Bengt; Fekadu, Makonnen; Behboudi, Shahriar; Kenne, Lennart; Morein, Bror

LOCATION: Department of Iscom Technology, the National Veterinary Institute, 750 07, Uppsala, Swed.

JOURNAL: Vaccine DATE: 1997 VOLUME: 15 NUMBER: 17/18 PAGES: 1820-1826

CODEN: VACCDE ISSN: 0264-410X LANGUAGE: English PUBLISHER: Elsevier Science Ltd.

3/3, K/8 (Item 8 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

127099693 CA: 127(7)99693d JOURNAL

Iscoms as delivery systems

AUTHOR(S): Morein, Bror; Bengtsson, Karin Loevgren

LOCATION: SLU, Dpt Vet. Microbiol, S-75123, Uppsala, Swed.

JOURNAL: Proc. Int. Symp. Controlled Release Biact. Mater. DATE: 1997

VOLUME: 24th, PAGES: 118 CODEN: PCRMZY ISSN: 1022-0178 LANGUAGE: English PUBLISHER: Controlled Release Society, Inc.

3/3, K/9 (Item 9 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

126249930 CA: 126(19)249930z JOURNAL

Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response

AUTHOR(S): Villacres-Eriksson, Maria; Behboudi, Shahriar; Morgan, Andrew J.; Trinchieri, Giorgio; Morein, Bror

LOCATION: Dep. Veterinary Microbiology, Swedish Univ. Agricultural Sciences, S-751 23, Uppsala, Swed.

JOURNAL: Cytokine DATE: 1997 VOLUME: 9 NUMBER: 2 PAGES: 73-82

CODEN: CYTI E9 ISSN: 1043-4666 LANGUAGE: English PUBLISHER: Academic

3/3, K/10 (Item 10 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

125056216 CA: 125(5)56216s PATENT

Saponin preparations and use thereof in ISCOMs

INVENTOR(AUTHOR): Cox, John Cooper; Coulter, Alan Robert; Morein, Bror; Lovgren-Bengtsson, Karin; Sundquist, Bo

LOCATION: Swed.

ASSIGNEE: Iscotec Ab

PATENT: PCT International ; WO 9611711 A1 DATE: 960425

APPLICATI ON: WO 95AU670 (951012) *AU 948732 (941012)

PAGES: 39 pp. CODEN: PIXD2 LANGUAGE: English

PATENT CLASSI FICATIONS:

CLASS: A61K-047/46A; A61K-047/28B; A61K-047/26B; C07G-003/00B; C07J-063/00B

DESIGNATED COUNTRIES: AU; CA; FI; JP; KR; NO; NZ; US

DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE

3/3, K/11 (Item 11 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

124185259 CA: 124(14)185259m JOURNAL
Isolation and quantification of Quillaja saponaria Molina saponins and
lipids in iscom matrix and iscoms
AUTHOR(S): Behboudi, Shahriar; Morein, Bror; Roennberg, Bengt
LOCATION: Department Veterinary Microbiology, Swedish University
Agricultural Sciences, 751 23, Uppsala, Swed.
JOURNAL: Vaccine DATE: 1995 VOLUME: 13 NUMBER: 17 PAGES: 1690-6
CODEN: VACCDE ISSN: 0264-410X LANGUAGE: English

3/3, K/12 (Item 12 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

124084241 CA: 124(7)84241u JOURNAL
Adjuvant activity of non-toxic Quillaja saponaria Molina components for
use in ISCOM matrix
AUTHOR(S): Ronnberg, Bengt; Fekadu, Makonnen; Morein, Bror
LOCATION: UK,
JOURNAL: Vaccine DATE: 1995 VOLUME: 13 NUMBER: 14 PAGES: 1375-82
CODEN: VACCDE ISSN: 0264-410X LANGUAGE: English

3/3, K/13 (Item 13 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

114115082 CA: 114(13)115082t PATENT
Sterol-containing iscom matrix with immunostimulating activity
INVENTOR(AUTHOR): Morein, Bror; Loevgren, Karin; Dalsgaard, Kristian;
Thurin, Jan; Sundquist, Bo
LOCATION: Swed.
PATENT: PCT International ; WO 9003184 A1 DATE: 900405
APPLICATION: WO 89SE528 (890928) *US 251576 (880930) *SE 891027 (890322)
*SE 892780 (890816)
PAGES: 48 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/39A; C07J-017/00B; C07J-063/00B
DESIGNATED COUNTRIES: AU; DK; FI; HU; JP; NO; SU; US
DESIGNATED REGIONAL: AT; BE; CH; DE; FR; GB; IT; LU; NL; SE

3/3, K/14 (Item 14 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

108226714 CA: 108(26)226714w JOURNAL
The requirement of lipids for the formation of immunostimulating
complexes (iscoms)
AUTHOR(S): Loevgren, Karin; Morein, Bror
LOCATION: Biomed., Natl. Vet. Inst., S-751 23, Uppsala, Swed.
JOURNAL: Biotechnol. Appl. Biochem DATE: 1988 VOLUME: 10 NUMBER: 2
PAGES: 161-72 CODEN: BABIEC ISSN: 0885-4513 LANGUAGE: English

3/3, K/15 (Item 15 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

105132044 CA: 105(15)132044p PATENT
Immunogenic complex and its use as an immune stimulant, vaccines and reagent
INVENTOR(AUTHOR): Mörén, Bror
LOCATION: Swed.
PATENT: European Pat. Appl. ; EP 180564 A2 DATE: 860507
APPLICATION: EP 85850326 (851016) *SE 845493 (841101)
PAGES: 65 pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/385A; A61K-039/44B; A61K-039/39B; A61K-045/05B
DESIGNATED COUNTRIES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE

3/3, K/16 (Item 16 from file: 399)
DIALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rights reserved.

101097625 CA: 101(12)97625x PATENT
Immunogenic protein or peptide complex and its use as an immune stimulant and as a vaccine
INVENTOR(AUTHOR): Mörén, Bror
LOCATION: Swed.
PATENT: European Pat. Appl. ; EP 109942 A2 DATE: 840530
APPLICATION: EP 83850273 (831013) *SE 82/5892 (821018)
PAGES: 43 pp. CODEN: EPXXDW LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/00; C07G-007/00
DESIGNATED COUNTRIES: AT; BE; CH; DE; FR; GB; IT; LI; LU; NL; SE
? e au=lovegren, karin?

Ref	Items	Index-term
E1	1	AU=LOVEGREN, JON C
E2	1	AU=LOVEGREN, JON C.
E3	0	*AU=LOVEGREN, KARI N?
E4	1	AU=LOVEGREN, L.
E5	1	AU=LOVEGREN, L. A.
E6	1	AU=LOVEGREN, LEVI A.
E7	1	AU=LOVEGREN, M
E8	1	AU=LOVEGREN, MEGHAN
E9	2	AU=LOVEGREN, N.
E10	23	AU=LOVEGREN, N. V.
E11	5	AU=LOVEGREN, NORMAN V.
E12	2	AU=LOVEGREN, NV

Enter P or PAGE for more
? e au=lovegren, K?

Ref	Items	Index-term
E1	3	AU=LOVGREN, K
E2	48	AU=LOVGREN, K.
E3	0	*AU=LOVGREN, K?
E4	10	AU=LOVGREN, KARI N
E5	1	AU=LOVGREN, KATHLEEN CAMILLE SLEDGE
E6	1	AU=LOVGREN, KERSTIN
E7	1	AU=LOVGREN, KJELL A V
E8	1	AU=LOVGREN, KJELL AKE VILHELM
E9	2	AU=LOVGREN, KRISTINA
E10	1	AU=LOVGREN, KURK INGVAR
E11	4	AU=LOVGREN, KURT
E12	4	AU=LOVGREN, KURT INGVAR

Enter P or PAGE for more

? s e1-e4

3 AU=LOVGREN, K
48 AU=LOVGREN, K.
0 AU=LOVGREN, K?
10 AU=LOVGREN, KARI N
61 E1-E4

S4

? s s4 and quil?

61 S4
25651 QUI L?
S5 2 S4 AND QUI L?

? t s5/3, k/1-5

>>>KW C option is not available in file(s): 399

5/3, K/1 (Item 1 from file: 50)
DI ALOG(R) File 50: CAB Abstracts
(c) 2009 CAB International. All rts. reserv.

0005938133 CAB Accession Number: 19882206901
Influenza virus ISCOMs: biochemical characterization.
Sundquist, B.; Lovgren, K.; Hoglund, S.; Mørein, B.
Nat. Vet. Inst., Box 7073, S-750 07 Uppsala, Sweden.
Vaccine vol. 6 (1): p. 44-48
Publication Year: 1988
ISSN: 0264-410X
Language: English
Record Type: Abstract
Document Type: Journal article

... and neuraminidase (NA) consist of a matrix, which is the micellar form of the glycoside, Quil A, in hydrophobic interaction with both the envelope glycoproteins (HA/NA). The Quil A bound to the ISCOM amounted to 50 microg/mg (5% of ISCOM protein. ISCOMs...

Sundquist, B.; Lovgren, K.; Hoglund, S.; Mørein, B.

5/3, K/2 (Item 1 from file: 35)
DI ALOG(R) File 35: Dissertation Abs Online
(c) 2009 ProQuest Info&Learning. All rts. reserv.

0996599 ORDER NO. NOT AVAILABLE FROM UNIVERSITY MICROFILMS INT'L.
CONSTRUCTION AND POTENTIAL OF THE ISCOM AS IMMUNOGEN (QUIL A, SAPONIN, VACCINE)
Author: LOVGREN, KARI N
Degree: FIL.
Year: 1987
Corporate Source/Institution: SVERIGES LANTBRUKSUNIVERSITET (SWEDEN) (0697)
Source: VOLUME 49/01- C OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 63. 52 PAGES
ISBN: 91-576-3202-2
Publisher: SVERIGES LANTBRUKSUNIVERSITET, S-750 07 UPPSALA, SWEDEN

CONSTRUCTION AND POTENTIAL OF THE ISCOM AS IMMUNOGEN (QUIL A, SAPONIN, VACCINE)
Author: LOVGREN, KARI N

The iscom-immunostimulating complex--is a highly immunogenic formulation of microbial membrane antigens. The adjuvant Quil A forms together with cholesterol a matrix into which amphipathic molecules are incorporated by hydrophobic...
? e au=ekstrom j?

Ref	Items	Index-term
E1	9	AU=EKSTROM, J. P.
E2	2	AU=EKSTROM, J. R.
E3	0	*AU=EKSTROM, J?
E4	1	AU=EKSTROM, JAMES L.
E5	2	AU=EKSTROM, JAMES R.
E6	1	AU=EKSTROM, JAMES V.
E7	1	AU=EKSTROM, JAN
E8	2	AU=EKSTROM, JAN PETRI
E9	1	AU=EKSTROM, JANNE
E10	1	AU=EKSTROM, JC
E11	8	AU=EKSTROM, JENNI FER L.
E12	15	AU=EKSTROM, JENNI FER L.

Enter P or PAGE for more
 ? e au=ekstrom jill

Ref	Items	Index-term
E1	3	AU=EKSTROM, JENS-OLA
E2	1	AU=EKSTROM, JESPER
E3	4	*AU=EKSTROM, JILL
E4	1	AU=EKSTROM, JL
E5	3	AU=EKSTROM, JM
E6	6	AU=EKSTROM, JMM
E7	5	AU=EKSTROM, JO
E8	3	AU=EKSTROM, JOEL L.
E9	7	AU=EKSTROM, JOEL L.
E10	1	AU=EKSTROM, JOHAN OLOF
E11	1	AU=EKSTROM, JOHN EDWARD
E12	1	AU=EKSTROM, JOHN PETER

Enter P or PAGE for more

? s e3-e4

	4	AU=EKSTROM, JILL
	1	AU=EKSTROM, JL
S6	5	E3-E4

? rd

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S7 4 RD (unique items)

? t s7/3, k/1-4

>>>KW C option is not available in file(s): 399

7/3, K/1 (Item 1 from file: 24)

DIALOG(R) File 24: CSA Life Sciences Abstracts
 (c) 2009 CSA. All rights reserved.

0002519716 I P ACCESSION NO: 5780257

Mechanism of Human S-Adenosylmethionine Decarboxylase Proenzyme Processing
 As Revealed by the Structure of the S68A Mutant

Tolbert, WD; Zhang, Y; Cottet, SE; Bennett, EM; Ekstrom, JL;
 Pegg, AE; Ealick, SE
 Department of Chemistry and Chemical Biology, Cornell University, Ithaca,
 New York 14853-1301, USA

Biochemistry (Washington), v 42, n 8, p 2386-2395, March 4, 2003
 PUBLICATION DATE: 2003

DOCUMENT TYPE: Journal Article
 RECORD TYPE: Abstract
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ISSN: 0006-2960
 FILE SEGMENT: Genetics Abstracts

Tolbert, WD; Zhang, Y; Cottet, SE; Bennett, EM; Ekstrom, JL;
 Pegg, AE; Ealick, SE

7/3, K/2 (Item 1 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rights reserved.

131189555 CA: 131(14)189555x JOURNAL
 Induction of antibody responses in the common mucosal immune system by
 respiratory syncytial virus immunostimulating complexes
 AUTHOR(S): Hu, K.-F.; Ekstrom, Jill; Merza, Malik; Lovgren-Bengtsson,
 Karin; Morein, Bror
 LOCATION: Department of Veterinary Microbiology, Section of Virology,
 College of Veterinary Medicine, Swedish University of Agricultural Sciences
 , S-751 23, Uppsala, Swed.
 JOURNAL: Med. Microbiol. Immunol. DATE: 1999 VOLUME: 187 NUMBER: 4
 PAGES: 191-198 CODEN: MM YAO ISSN: 0300-8584 LANGUAGE: English
 PUBLISHER: Springer-Verlag

7/3, K/3 (Item 2 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rights reserved.

127233551 CA: 127(17)233551m PATENT
 Iscom or iscom-matrix comprising a mucus targetting substance and
 optionally, an antigen
 INVENTOR(AUTHOR): Morein, Bror; Lovgren, Bengtsson Karin; Ekstrom, Jill
 LOCATION: Swed.
 ASSIGNEE: Morein, Bror; Lovgren Bengtsson, Karin; Ekstrom, Jill
 PATENT: PCT International ; WO 9730728 A1 DATE: 19970828
 APPLICATION: WO 97SE289 (19970220) *SE 96647 (19960221)
 PAGES: 144 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: A61K-039/39A
 DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
 CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC;
 LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD;
 SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; AM; AZ; BY; KG; KZ;
 MD; RU; TJ; TM DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE
 ; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
 CM; GA; GN; ML; MR; NE; SN; TD; TG

7/3, K/4 (Item 3 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rights reserved.

127233549 CA: 127(17)233549s PATENT
 Iscom or iscom-matrix comprising hydrophobic receptor molecules for
 antigenic substances
 INVENTOR(AUTHOR): Morein, Bror; Lovgren, Bengtsson Karin; Ekstrom, Jill
 LOCATION: Swed.
 ASSIGNEE: Morein, Bror; Lovgren Bengtsson, Karin; Ekstrom, Jill

10562866.txt

PATENT: PCT International ; WO 9730726 A1 DATE: 19970828

APPLICATION: WO 97SE287 (19970220) *SE 96648 (19960221)

PAGES: 38 pp. CODEN: PIXXD2 LANGUAGE: Swedish

PATENT CLASSIFICATIONS:

CLASS: A61K-039/39A

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC;
LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD;
SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; AM; AZ; BY; KG; KZ;
MD; RU; TJ; TM DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE
; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;
OM; GA; GN; ML; MR; NE; SN; TD; TG
? e au=r anl und, katari na?

Ref	Items	Index-term
E1	1	AU=RANLUND, K.
E2	3	AU=RANLUND, KATARI NA
E3	0	*AU=RANLUND, KATARI NA?
E4	1	AU=RANLUND, R.
E5	1	AU=RANLV, J.
E6	12	AU=RANLY D
E7	106	AU=RANLY D M
E8	3	AU=RANLY D.
E9	36	AU=RANLY D. M
E10	38	AU=RANLY DM
E11	1	AU=RANLY DON
E12	17	AU=RANLY DON M

Enter P or PAGE for more

? s e1-e3

1	AU=RANLUND, K.
3	AU=RANLUND, KATARI NA
0	AU=RANLUND, KATARI NA?
S8	4 E1-E3

? rd

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S9 3 RD (unique items)

? t s9/3, k/1-3

>>>KW C option is not available in file(s): 399

9/3, K/1 (Item 1 from file: 50)

DI ALOG(R) File 50: CAB Abstracts

(c) 2009 CAB International. All rts. reserv.

0007969768 CAB Accession Number: 20002220448

Impaired immunogenicity of immunostimulating complexes (iscoms) by
administration in slow-release formulations.

Johansson, M; Ramlund, K; Lovgren-Bengtsson, K.

Swedish University of Agricultural Sciences, Department of Veterinary
Microbiology, Section of Virology, BMC, Box 585, S-751 23 Uppsala, Sweden.

Microbes and Infection vol. 2 (9): p.1003-1010

Publication Year: 2000

Language: English

Record Type: Citation

Document Type: Journal article

Johansson, M; Ramlund, K; Lovgren-Bengtsson, K.

9/3, K/2 (Item 1 from file: 399)
 DI ALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rights reserved.

145187050 CA: 145(10)187050u PATENT
 Vaccine compositions comprising Staphylococcal or Streptococcal
 fibronectin binding protein, ISCOM matrix, liposomes and other antigen
 INVENTOR(AUTHOR): Morein, Bror; Loevgren-Bengtsson, Karin; Ramlund,
 Katarina; Fromgren, Birgitta; Ekstroem, Jill; Baschunan, Carlos
 LOCATION: Swed.
 ASSIGNEE: Isconova AB
 PATENT: PCT International ; WO 200678213 A1 DATE: 20060727
 APPLICATION: WO 2006SE82 (20060120) *US 2005PV593504 (20050120)
 PAGES: 88 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 IPCR/8 + Level Value Position Status Version Action Source Office:
 A61K-0039/085 A I F B 20060101 H SE
 A61K-0039/09 A I L B 20060101 H SE
 A61K-0039/39 A I L B 20060101 H SE
 A61P-0031/04 A I L B 20060101 H SE
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
 BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
 GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK;
 LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ;
 OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR;
 TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH;
 ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
 NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
 MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM;
 ZW AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

9/3, K/3 (Item 2 from file: 399)
 DI ALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rights reserved.

142133049 CA: 142(8)133049v PATENT
 Quil A fraction with low toxicity for adjuvant application
 INVENTOR(AUTHOR): Morein, Bror; Loevgren Bengtsson, Karin; Ekstroem, Jill
 ; Ramlund, Katarina
 LOCATION: Swed.
 ASSIGNEE: Isconova AB
 PATENT: PCT International ; WO 200502620 A1 DATE: 20050113
 APPLICATION: WO 2004SE1038 (20040707) *SE 20031998 (20030707)
 PAGES: 62 pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:
 CLASS: A61K-039/39A
 DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
 BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
 GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
 LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
 PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
 UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW; MZ;
 ; NA; SD; SL; SZ; TZ; UG; ZM; ZW AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
 BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;
 PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR;
 NE; SN; TD; TG
 ? e au=hu, kefei ?

Ref Items Index-term
 E1 4 AU=HU, KEDING
 E2 10 AU=HU, KEFEI

E3 0 *AU=HU, KEFEI ?
 E4 1 AU=HU, KEFENG
 E5 1 AU=HU, KEHENG
 E6 1 AU=HU, KEHUA
 E7 1 AU=HU, KEHUI
 E8 1 AU=HU, KEHYUEN
 E9 1 AU=HU, KEI - JI
 E10 1 AU=HU, KEI JI
 E11 1 AU=HU, KEI YI
 E12 6 AU=HU, KEJI

Enter P or PAGE for more

? s e2-e3

10 AU=HU, KEFEI
 0 AU=HU, KEFEI ?

S10

10 E2- E3

? rd

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S11 10 RD (unique items)

? t s11/3, k/1-10

>>>KW C option is not available in file(s): 399

11/3, K/1 (Item 1 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

151273683 CA: 151(12)273683h JOURNAL

Quality standard for compound Ruangan granules

AUTHOR(S): Hu, Kefei; Zheng, Q ngping; Li, Yonghua; Du, Yukai

LOCATION: School of Public Health, Tongji Medical College, Huazhong
 University of Science and Technology, Wuhan, Peop. Rep. China, 430030

JOURNAL: Zhongchengyao (Zhongchengyao) DATE: 2009 VOLUME: 31 NUMBER: 3

PAGES: 409-413 CODEN: ZHONBS ISSN: 1001-1528 LANGUAGE: Chinese

PUBLISHER: Guojia Shipin Yaopin Jiaodu Guanlij u, Xixi Zhongxin
 Zhongchengyao Xixi zhan

11/3, K/2 (Item 2 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rts. reserv.

151108352 CA: 151(5)108352s PATENT

Medical composition with antioxidative and anti-aging functions and its
 preparation

INVENTOR(AUTHOR): Hu, Kefei

LOCATION: Peop. Rep. China,

ASSIGNEE: Beijing Increase Pharmaceutical Science and Technology Co.,
 Ltd.

PATENT: Faming Zh. Sh. Gong. Shuom; CN 101450088 A DATE: 20090610

APPLICATION: CN 10178510 (20071130)

PAGES: 7pp. CODEN: CNXXEV LANGUAGE: Chinese

PATENT CLASSIFICATIONS:

IPC/8 + Level Value Position Status Version Action Source Office:

A61K-0036/185	A	I	F	B	20060101		H	CN
A61P-0039/06	A	I	L	B	20060101		H	CN
A23L-0001/30	A	I	L	B	20060101		H	CN
A61K-0031/355	A	N	L	B	20060101		H	CN
A61K-0031/375	A	N	L	B	20060101		H	CN

11/3, K/3 (Item 3 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rts. reserv.

151063912 CA: 151(3)63912f PATENT
 Method for manufacturing traditional chinese medicine composition for
 resisting oxidation and retarding aging
 INVENTOR(AUTHOR): Hu, Kefei
 LOCATION: Peop. Rep. China,
 ASSIGNEE: Beijing Increase Pharmaceutical Technology Co., Ltd.
 PATENT: Faming Zh. Sh. Gong. Shuom; CN 101433634 A DATE: 20090520
 APPLICATION: CN 10177491 (20071116)
 PAGES: 8pp. CODEN: ONXXEV LANGUAGE: Chinese
 PATENT CLASSIFICATIONS:

IPC/8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0036/87	A	I	F	B	20060101	H	CN
A61P-0039/06	A	I	L	B	20060101	H	CN
A23L-0001/30	A	I	L	B	20060101	H	CN

11/3, K/4 (Item 4 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rts. reserv.

149017707 CA: 149(1)17707d PATENT
 Use of lipid containing particles such as liposomes, iscom and/or iscom
 matrix and posintros, comprising Quillaja saponins, for the treatment of
 cancer
 INVENTOR(AUTHOR): Hu, Kefei; Mbrein, Bror
 LOCATION: Swed.
 ASSIGNEE: Duecom
 PATENT: PCT International ; WO 200863129 A1 DATE: 20080529
 APPLICATION: WO 2007SE50878 (20071120) *US 2006PV866445 (20061120)
 PAGES: 86pp. CODEN: PIXXD2 LANGUAGE: English
 PATENT CLASSIFICATIONS:

IPC/8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0031/704	A	I	F	B	20060101	H	SE
A61K-0039/39	A	I	L	B	20060101	H	SE
A61P-0035/00	A	I	L	B	20060101	H	SE

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BH; BR; BW;
 BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI;
 GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP;
 KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY;
 MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK;
 SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ DESIGNATED REGIONAL: AT; BE; BG; CH;
 ; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC;
 MT; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
 ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG;
 ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

11/3, K/5 (Item 5 from file: 399)
 DIALOG(R) File 399: CA SEARCH(R)
 (c) 2009 American Chemical Society. All rts. reserv.

148305998 CA: 148(14)305998w CONFERENCE PROCEEDING
 New ISCOMs meet unsettled vaccine demands
 AUTHOR(S): Mbrein, Bror; Hu, Kefei; Loevgren, Karin; D'Hondt, Erik
 LOCATION: Department of Medical Sciences, Section of Virology, University
 Hospital, Iscovent AB, Uppsala University, Uppsala, Swed.
 JOURNAL: Vaccine Adjuvants Delivery Syst. (Vaccine Adjuvants and Delivery

10562866.txt
Systems) EDITOR: Singh, Manmohan (Ed), DATE: 2007 PAGES: 191-222
CODEN: 69KEQD LANGUAGE: English PUBLISHER: John Wiley & Sons, Inc.,
Hoboken, N. J ISBN: 978-0-471-73907-4

11/3, K/6 (Item 6 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

147474672 CA: 147(22)474672v PATENT
Composition of traditional Chinese medicine tablet for treating
gynecopathy and its preparation method thereof
INVENTOR(AUTHOR): Hu, Kefei
LOCATION: Peop. Rep. China,
ASSIGNEE: Beijing Yinke Ruisi Bioproduct Research Institute
PATENT: Faming Zh. Sh. Gong. Shuom; CN 101049408 A DATE: 20071010
APPLICATION: CN 10066924 (20060403)
PAGES: 9pp. CODEN: CNXXEV LANGUAGE: Chinese
PATENT CLASSIFICATION:

IPC(R 8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0036/896	A	I	F	B	20060101	H	CN
A61K-0009/20	A	I	L	B	20060101	H	CN
A61P-0015/00	A	I	L	B	20060101	H	CN

11/3, K/7 (Item 7 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

146087526 CA: 146(5)87526f PATENT
Manufacture of traditional Chinese medicine tablet for treating cervical
spondyl osis
INVENTOR(AUTHOR): Hu, Kefei
LOCATION: Peop. Rep. China,
ASSIGNEE: Beijing Yinke Ruisi Bioproduct Research Institute
PATENT: Faming Zh. Sh. Gong. Shuom; CN 1872229 A DATE: 20061206
APPLICATION: CN 10080714 (20060512)
PAGES: 14pp. CODEN: CNXXEV LANGUAGE: Chinese
PATENT CLASSIFICATION:

IPC(R 8 + Level	Value	Position	Status	Version	Action	Source	Office:
A61K-0036/804	A	I	F	B	20060101	H	CN
A61K-0009/20	A	I	L	B	20060101	H	CN
A61P-0019/02	A	I	L	B	20060101	H	CN
A61K-0035/64	A	N	L	B	20060101	H	CN
A61K-0035/56	A	N	L	B	20060101	H	CN

11/3, K/8 (Item 8 from file: 399)
DI ALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rts. reserv.

142021880 CA: 142(2)21880c JOURNAL
Safety and efficacy of immune-stimulating complex-based antigen delivery
systems for neonatal immunization against respiratory syncytial virus
infection
AUTHOR(S): Regner, Matthias; Culley, Fiona; Fontannaz, Paola; Hu, Kefei;
Morein, Bror; Lambert, Paul-Henri; Openshaw, Peter; Siegrist, Claire-Anne
LOCATION: CMU, Departments of Pathology and Paediatrics, WHO
Collaborating Center for Vaccinology, University of Geneva, 1211 4, Geneva,
Switz.
JOURNAL: Microbes Infect. (Microbes and Infection) DATE: 2004 VOLUME: 6
NUMBER: 7 PAGES: 666-675 CODEN: MCI NFS ISSN: 1286-4579
PUBLISHER IDENTIFIER: 1286-4579(04)00102-9 LANGUAGE: English

PUBLISHER: Elsevier Science B. V.

11/3, K/9 (Item 9 from file: 399)

DIALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

136139953 CA: 136(9)139953h JOURNAL

Determination of baicalin in Pizhenqing granules with HPLC

AUTHOR(S): Lu, Jinqing; Yu, Nancai; Li, Jun; Hu, Kefei; Zhao, Xianga

LOCATION: Hubei College of Traditional Chinese Medicine, Wuhan, Peop.

Rep. China, 430061

JOURNAL: Zhongguo Yi yuan Yaoxue Zazhi DATE: 2001 VOLUME: 21 NUMBER: 11

PAGES: 661-663 CODEN: ZYYAEP ISSN: 1001-5213 LANGUAGE: Chinese

PUBLISHER: Zhongguo Yi yuan Yaoxue Zazhi Bianjibu

11/3, K/10 (Item 10 from file: 399)

DIALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

134152446 CA: 134(11)152446y JOURNAL

Study on quality specifications of Pizhenqing granules

AUTHOR(S): Yu, Nancai; Hu, Kefei; Zhang, Jiemei; Xue, Sha

LOCATION: First Hospital of Wuhan, Wuhan, Peop. Rep. China, 430022

JOURNAL: Zhongguo Yi yuan Yaoxue Zazhi DATE: 2000 VOLUME: 20 NUMBER: 6

PAGES: 327-329 CODEN: ZYYAEP ISSN: 1001-5213 LANGUAGE: Chinese

PUBLISHER: Zhongguo Yi yuan Yaoxue Zazhi Bianjibu

? s (quil\$ near A) and complex

0 QUI L\$ NEAR A

8408913 COMPLEX

S12 0 (QUI L\$ NEAR A) AND COMPLEX

? s quil and complex

3082 QUI L

8408913 COMPLEX

S13 308 QUI L AND COMPLEX

? s s13 and quil? and complex

308 S13

25651 QUI L?

8408913 COMPLEX

S14 308 S13 AND QUI L? AND COMPLEX

? s s14 and saponin

308 S14

68054 SAPONIN

S15 88 S14 AND SAPONIN

? rd

>>>Duplicate detection is not supported for File 393.

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S16 50 RD (unique items)

?

? t s16/3, k/1-50

>>>KW C option is not available in file(s): 399

16/3, K/1 (Item 1 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

0021139415 BIOSIS NO.: 200900480852

ISCOMs and ISCOMATRIX (TM)

10562866.txt

AUTHOR: Sun Hong-Xiang (Reprint); Xie Yong; Ye Yi-Ping
AUTHOR ADDRESS: Zhejiang Univ, Coll Anim Sci, Minist Agr, Key Lab Anim
Epidemiol and Immunol Prevent, Kai xuan Rd 268, Hangzhou 310029,
Zhejiang, Peoples R China**Peoples R China
AUTHOR E-MAIL ADDRESS: sunhx@zju.edu.cn
JOURNAL: Vaccine 27 (33): p4388-4401 JUL 16 2009 2009
ITEM IDENTIFIER: doi: 10.1016/j.vaccine.2009.05.032
ISSN: 0264-410X
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Immunostimulatory complexes (ISCOMs) are particulate antigen delivery systems composed of antigen, cholesterol, phospholipid and saponin, while ISCOMATRIX (TM) is a particulate adjuvant comprising cholesterol, phospholipid and saponin but without antigen. The combination of an antigen with ISCOMATRIX (TM) is called an ISCOMATRIX...

...the advantages of a particulate carrier system with the presence of an in-built adjuvant (Quil A) and consequently have been found to be more immunogenic, while removing its haemolytic activity of the saponin, producing less toxicity. ISCOMs and ISCOMATRIX (TM) vaccines have now been shown to induce strong...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ...saponin; ...

...immunostimulatory complex {ISCOM}

16/3, K/2 (Item 2 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

0021133740 BIOSIS NO.: 200900475177

Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs)

AUTHOR: Pham Hoang L; Ross Benjamin P (Reprint); McGarry Ross P; Shaw P
Nicholas; Davies Nigel M

AUTHOR ADDRESS: Univ Queensland, Sch Pharm Brisbane, Qld 4072, Australia**
Australia

AUTHOR E-MAIL ADDRESS: b.ross@pharmacy.uq.edu.au

JOURNAL: International Journal of Pharmaceutics (Kidlington) 376 (1-2): p
123-133 JUL 6 2009 2009

ITEM IDENTIFIER: doi: 10.1016/j.ijpharm.2009.04.011

ISSN: 0378-5173

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs)

ABSTRACT: The aim of the study was to prepare cationic ISCOMs using cationic derivatives of the saponin Quil A. The polyamines ethylenediamine, spermidine and spermine were conjugated with the glucuronic acid moiety of Quil A. The aqueous solubility of the derivatives increased with decreasing pH, and the pKa...

...the method of hydration of freeze-dried monophasic systems, the interaction of each of the Quil A derivatives with phosphatidylcholine and cholesterol, at a mass ratio of 4:4:2 and...

10562866.txt

...were present in the systems prepared at pH 7.4, hence the ternary system of Quil A spermine derivative, phosphatidylcholine and cholesterol was further investigated at pH 7.4 using a...

...like structures were less homogeneous and more irregular in shape than ISCOMs prepared from unmodified Quil A. Colloidal particles with positive zeta potential were produced and may find application in the...

DESCRIPTORS:

...ORGANISMS: Quillaja saponaria (Rosaceae

CHEMICALS & BIOCHEMICALS: ...Quil A cationic derivative...

...cationic immune-stimulating complex--

16/3, K/3 (Item 3 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

0020390120 BIOSIS NO.: 200800437059

Saponins from Quillaja saponaria Molina: Isolation, characterization and ability to form immunostimulatory complexes (ISCOMs)

AUTHOR: Pham Hoang L; Ross Benjamin P; McGeary Ross P; Shaw P Nicholas; Hewavitharana Aritha K; Davies Nigel M (Reprint)

AUTHOR ADDRESS: Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia**
Australia

AUTHOR E-MAIL ADDRESS: n.davies@pharmacy.uq.edu.au

JOURNAL: Current Drug Delivery 3 (4): p389-397 OCT 2006 2006

ISSN: 1567-2018

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Saponins from Quillaja saponaria Molina: Isolation, characterization and ability to form immunostimulatory complexes (ISCOMs)

...ABSTRACT: due to their immunostimulatory effects. They are colloidal particles typically comprised of phospholipids, cholesterol and Quil A, a crude mixture of saponins extracted from the bark of Quillaja saponaria Molina. We have previously shown that ISCOMs can be prepared by ether injection wherein...

...and cholesterol in a mass ratio of 5: 2 is injected into a solution of Quil A at a mass ratio of 7 lipids: 3 Quil A. The aim of this study was firstly to isolate and characterise discrete fractions of Quil A and secondly to investigate which of these fractions were able to form ISCOMs by the method of ether injection. Six fractions of Quil A were isolated by semi-preparative reverse phase high performance liquid chromatography (RP-HPLC) and...

...and a minor amount of ISCOMs. The remaining two hydrophilic, low molecular weight fractions of Quil A did not produce ISCOMs, instead liposomes and helical structures predominated in the samples.

...REGISTRY NUMBERS: Quil A...

...Quil A

DESCRIPTORS:

...ORGANISMS: Quillaja saponaria (Rosaceae

CHEMICALS & BIOCHEMICALS: ...saponin; ...

...Quil A...

...Quil A

MISCELLANEOUS TERMS: ...immuno stimulatory complex
CONCEPT CODES:

16/3, K/4 (Item 4 from file: 5)
DI ALOG(R) File 5: Biosi s Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

0019588648 BIOSIS NO.: 200700248389
Cage-like complexes formed by DOTAP, Quil-A and cholesterol
AUTHOR: Lendemans D G; Egert A M; Hook S; Rades T (Reprint)
AUTHOR ADDRESS: Univ Otago, Sch Pharm, POB 913, Dunedin, New Zeal and**New
Zeal and
AUTHOR E-MAIL ADDRESS: thomas.rades@stonebow.otago.ac.nz
JOURNAL: International Journal of Pharmaceutics (Kidington) 332 (1-2): p
192-195 MAR 6 2007 2007
ISSN: 0378-5173
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Cage-like complexes formed by DOTAP, Quil-A and cholesterol

...ABSTRACT: cationic lipid dioleoyl-trimethyl-ammonium-propane (DOTAP).
The self-assembled colloidal structures formed by DOTAP Quil-A and
cholesterol were characterised using transmission electron microscopy and
laser Doppler velocimetry. Samples were...

...weight proportions of DOTAP displayed phase separation phenomena. Thus,
 whilst DOTAP can be incorporated with Quil-A and cholesterol to
 form cage-like particles, it appears to be unsuitable to prepare...

...REGISTRY NUMBERS: Quillaja saponin
DESCRIPTORS:
ORGANISMS: Quillaja (Rosaceae...
CHEMICALS & BIOCHEMICALS: ...Quillaja saponin; ...

...cage-like complex; ...

...quil-A

16/3, K/5 (Item 5 from file: 5)
DI ALOG(R) File 5: Biosi s Previews(R)
(c) 2009 The Thomson Corporation. All rts. reserv.

18409266 BIOSIS NO.: 200510103766
Immuno-stimulating complexes prepared by ethanol injection
AUTHOR: Lendemans Dirk G; Myschik Julia; Hook Sarah; Rades Thomas (Reprint)
AUTHOR ADDRESS: Univ Otago, Sch Pharm, Dunedin, New Zeal and**New Zeal and
AUTHOR E-MAIL ADDRESS: thomas.rades@stonebow.otago.ac.nz
JOURNAL: Journal of Pharmacy and Pharmacology 57 (6): p729-733 JUN 05 2005
ISSN: 0022-3573
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

...ABSTRACT: and the resulting solution was rapidly injected into a
stirred, aqueous solution of the triterpene-saponin mixture
Quil-A. The reversed experiment was also carried out by adding the
aqueous Quil-A solution to a solution of
cholesterol/phosphatidylcholine dissolved in ethanol. This was done by
either rapid injection or dropwise addition of the aqueous Quil-A

10562866.txt

solution. The colloidal dispersions obtained by ethanol injection and reversed addition were compared with...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... saponin;

MISCELLANEOUS TERMS: immuno-stimulating complex

CONCEPT CODES:

16/3, K/6 (Item 6 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

17561158 BIOSIS NO.: 200300516521

The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.

AUTHOR: Robson Neil C (Reprint); Beacock-Sharp Helen; Donachie Anne M; Mowat Allan M

AUTHOR ADDRESS: Department of Immunology and Bacteriology, University of Glasgow, Western Infirmary, Glasgow, G11 6NT, UK**UK

AUTHOR E-MAIL ADDRESS: ncr1p@clinmed.gla.ac.uk

JOURNAL: Immunology 110 (1): p95-104 September 2003 2003

MEDIUM: print

ISSN: 0019-2805

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Immune stimulating complexes (ISCOMs) containing the saponin adjuvant Quil A are vaccine adjuvants that promote a wide range of immune responses in vivo, including...

... REGISTRY NUMBERS: Quil A

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: ... Quil A...

... immune stimulating complex;

16/3, K/7 (Item 7 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

17396376 BIOSIS NO.: 200300355095

Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.

AUTHOR: Robson Neil C (Reprint); Beacock-Sharp Helen; Donachie Anne M; Mowat Allan M

AUTHOR ADDRESS: Department of Immunology and Bacteriology, University of Glasgow, Western Infirmary, Glasgow, G11 6NT, UK**UK

AUTHOR E-MAIL ADDRESS: ncr1p@clinmed.gla.ac.uk

JOURNAL: Immunology 109 (3): p374-383 July 2003 2003

MEDIUM: print

ISSN: 0019-2805

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

... CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.

ABSTRACT: Immune stimulating complexes (ISCOMs) containing the

10562866.txt

saponin adjuvant Quil A are vaccine adjuvants that induce a wide range of immune responses in vivo, including strong class I major histocompatibility complex (MHC) -restricted cytotoxic T-lymphocyte activity. However, the antigen-presenting cell responsible for the induction...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: major histocompatibility complex class II

MISCELLANEOUS TERMS: ...major histocompatibility complex class II loading

CONCEPT CODES:

16/3, K/8 (Item 8 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

13915765 BIOSIS NO.: 199799549825

Iscoms containing purified Quilaja saponins upregulate both Th1-like and Th2-like immune responses

AUTHOR: Sjölander Anders (Reprint); Van't Land Belinda; Bengtsson Karin Lovgren

AUTHOR ADDRESS: Immunoparasitol. Unit, Walter Eliza Hall Inst. Med. Research, P.O. Royal Melbourne Hosp., VIC 3050, Australia**Australia

JOURNAL: Cellular Immunology 177 (1): p69-76 1997 1997

ISSN: 0008-8749

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Iscoms containing purified Quilaja saponins upregulate both Th1-like and Th2-like immune responses

ABSTRACT: The immune stimulating complex (iscom) is built up by antigen, cholesterol, phospholipids, and adjuvant active Quilaja saponins. Previous studies have shown that iscoms containing Quil A (a semipurified preparation of saponins) efficiently induce antibody and cell-mediated immune responses. In this study, we demonstrate that iscoms containing a mixture of two purified low toxicity Quilaja saponin fractions (ISCOPEP 703) are able to upregulate both Th1-like and Th2-like immune responses...

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS:

MISCELLANEOUS TERMS: ADJUVANT ACTIVE QUILAJA SAPONINS...

...IMMUNE STIMULATING COMPLEX;

CONCEPT CODES:

16/3, K/9 (Item 9 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2009 The Thomson Corporation. All rights reserved.

12930533 BIOSIS NO.: 199598398366

The role of Quil A in the adjuvanticity of ISCOMS

BOOK TITLE: The 9th International Congress of Immunology

AUTHOR: Maloy K J; Donachie A M; Mowat A M

BOOK AUTHOR/EDITOR: 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY

AUTHOR ADDRESS: Dep. Immunol., Univ. Glasgow, Glasgow G11 6NT, UK**UK p585 1995

BOOK PUBLISHER: 9th International Congress of Immunology {a}, San

10562866.txt

Francisco, California, USA

CONFERENCE/ MEETING: Meeting Sponsored by the American Association of Immunologists and the International Union of Immunological Societies San Francisco, California, USA July 23-29, 1995; 19950723

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

The role of Quil A in the adjuvanticity of ISCOMs

... REGISTRY NUMBERS: QUIL A

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: QUIL A

MISCELLANEOUS TERMS: IMMUNE STIMULATING COMPLEX; ...

... QUIL A ...

... SAPONIN ADJUVANT

CONCEPT CODES:

16/3, K/10 (Item 10 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

12102174 BIOSIS NO.: 199497123459

Vaccination with immunodominant peptides encapsulated in Quil

A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells

AUTHOR: Lipford Grayson B; Wagner Hermann; Heeg Klaus (Reprint)

AUTHOR ADDRESS: Inst. Med. Microbiol. Hygiene, Tech. Univ. Munich, Trogerstr. 4a, 81675 Munich, Germany**Germany

JOURNAL: Vaccine 12 (1): p73-80 1994 1994

ISSN: 0264-410X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Vaccination with immunodominant peptides encapsulated in Quil

A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells

ABSTRACT: Immunostimulating complexes (ISCOMs), containing lipids, the saponin Quil A, and proteinaceous antigens, have been proven to vaccinate effectively CD8+ cytolytic T cells in...

...restricted to hydrophobic proteins or fatty acid-derivatized proteins or peptides. We therefore analysed whether Quil A-containing liposomes are an effective vehicle to shuttle hydrophilic proteins or peptides into the...

...lipid dry-down method followed by resuspension with an aqueous solution containing protein/peptide and Quil A and then an extrusion step. Quil A-containing liposomes are an effective means to elicit a CD8+ CTL response to peptide...

...the versatility of this approach. The elicited response was peptide-specific, peptide dose-dependent and Quil A was necessary. Vaccination with liposomes entrapping the whole ovalbumin molecule or an extended (OVA...

...responsive to the immunodominant OVA peptide 256-264, implying cellular internalization and correct processing. Thus Quil A-containing liposomes appear to be a versatile vehicle to vaccinate CD8+ T cells in ...

... REGISTRY NUMBERS: QUIL A

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: QUIL A

MISCELLANEOUS TERMS: IMMUNOSTIMULATING COMPLEX;
CONCEPT CODES:

16/3, K/11 (Item 11 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2009 The Thomson Corporation. All rights reserved.

09159847 BIOSIS NO.: 198885128738

LOCAL REACTIONS OF THE SAPONIN QUIL A AND A QUIL A

CONTAINING ISCOM MEASLES VACCINE AFTER INTRAMUSCULAR INJECTION OF RATS A
COMPARISON WITH THE EFFECT OF DPT-POLIO VACCINE

AUTHOR: SPEIJERS G J A (Reprint); DANSE L H J C; BEUVERY E C; STRIK J J T W
A; VOS J G

AUTHOR ADDRESS: LAB TOXICOOL, NATL INST PUBLIC HEALTH ENVIRON HYGIENE, PO
BOX 1, 3720 BA BILTHOVEN, NETHERLANDS**NETHERLANDS

JOURNAL: Fundamental and Applied Toxicology 10 (3): p425-430 1988

ISSN: 0272-0590

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

LOCAL REACTIONS OF THE SAPONIN QUIL A AND A QUIL A

CONTAINING ISCOM MEASLES VACCINE AFTER INTRAMUSCULAR INJECTION OF RATS A
COMPARISON WITH THE EFFECT...

... ABSTRACT: toxicity study was performed to investigate local reactions
and hematological changes after immunization of Quillai A (Quil A; 50 or 600 .mu.g/ml) an essential component of an
immunostimulating complex (iscom), a novel form of a subunit
vaccine, and of iscom measles vaccine containing 360 .mu.g Quil
A/ml. The effects were compared with those caused by a sterile
phosphate-buffered saline...

... in rats injected with DPT-polio vaccine, iscom measles vaccine, and the
high dose of Quil A. The most intense granulomatous inflammatory
reaction, mainly consisting of activated macrophages, was observed at...

... nodes in all animals of both vaccine groups were activated, indicating a
good immune response. Quil A in the highest concentration caused in
all animals a different type of inflammatory reaction, characterized
mainly by a proliferation of fibroblasts. The low-concentration
Quil A revealed an inflammatory reaction only in one animal.
Considering the absence of local and hematological effects it can be
concluded that there are no objections against the use of Quil A in
an iscom vaccine at a concentration of 50 .mu.g/ml vaccine.

... REGISTRY NUMBERS: QUIL A

DESCRIPTORS: QUILLAIA A LYMPH NODE DIPHtheria- PERTUSSIS- TETANUS- POLIO
VACCINE INFLAMMATION

DESCRIPTORS:

CHEMICALS & BIOCHEMICALS: QUIL A

16/3, K/12 (Item 1 from file: 24)

DIALOG(R) File 24: CSA Life Sciences Abstracts

(c) 2009 CSA. All rights reserved.

0002505392 IP ACCESSION NO: 5705663

Dendritic cell maturation enhances CD8 super(+) T-cell responses to
exogenous antigen via a proteasome-independent mechanism of major

10562866.txt

histocompatibility complex class I loading

Robson, NC; Beacock-Sharp, H; Donachie, AM; Mowat, AM
Department of Immunology and Bacteriology, University of Glasgow, Western
Infirmary, Glasgow, G11 6NT, UK, [mailto:ncr1p@clinmed.gla.ac.uk]

Immunology, v 109, n 3, p 374-383, July 2003

PUBLICATION DATE: 2003

DOCUMENT TYPE: Journal Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ISSN: 0019-2805

FILE SEGMENT: Immunology Abstracts

...super(+) T-cell responses to exogenous antigen via a
proteasome-independent mechanism of major histocompatibility complex
class I loading

ABSTRACT:

Immune stimulating complexes (ISCOMS) containing the saponin
adjuvant Quil A are vaccine adjuvants that induce a wide range of
immune responses in vivo, including strong class I major histocompatibility
complex (MHC)-restricted cytotoxic T-lymphocyte activity. However,
the antigen-presenting cell responsible for the induction...

DESCRIPTORS: Antigen processing; ISCOMS; Lymphocytes T; Major
histocompatibility complex; Multicatalytic endopeptidase
complex; CD8 antigen; ovalbumin; chloroquine; brefeldin A

16/3, K/13 (Item 2 from file: 24)
DIALOG(R) File 24: CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved.

0001923863 IP ACCESSION NO: 4440396
Oral vaccination with immune stimulating complexes

Mowat, AM; Smith, RE; Donachie, AM; Furrie, E; Grdic, D; Lycke, N
Department of Immunology, University of Glasgow, Western Infirmary, Glasgow
G11 6NT, Scotland, UK

Immunology Letters, v 65, n 1-2, p 133-140, January 1, 1999

PUBLICATION DATE: 1999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English

ISSN: 0165-2478

FILE SEGMENT: Immunology Abstracts; Medical & Pharmaceutical Biotechnology
Abstracts

ABSTRACT:

... purified antigens. Here we describe our experience with lipophilic
immune stimulating complexes (ISCOMS) containing the saponin adjuvant
Quil A. When given orally, ISCOMS containing the model protein
antigen ovalbumin (OVA) induce a wide...

DESCRIPTORS: Nitric oxide; Vaccines; ISCOMS; Major histocompatibility
Page 23

10562866.txt

complex; Lymphocytes T; Interleukin 12; Interleukin 1;
Interleukin 6; Cholera; Immunoglobulin A

16/3, K/14 (Item 3 from file: 24)
DI ALOG(R) File 24: CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved.

0001079559 IP ACCESSION NO: 2615276
On the structure of immune-stimulating saponin-lipid complexes
(iscoms).

Kersten, GFA; Spijkstra, A; Beuvery, EC; Grommelin, DJA
Dep. Inact. Viral Vaccine, Natl. Inst. Public Health and Environ. Prot.
(RIVM), P.O. Box 1, 3720 BA, Bilthoven, Netherlands

Biochimica et Biophysica Acta, v 1062, n 2, p 165-171, 1991
ADDL. SOURCE INFO: Biochimica et Biophysica Acta [BIOCHIM BIOPHYS. ACTA.],
vol. 1062, no. 2, pp. 165-171, 1991
PUBLICATION DATE: 1991

DOCUMENT TYPE: Journal Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English
ISSN: 0167-4838
FILE SEGMENT: Biological Membranes (Biochemistry Abstracts 1)

On the structure of immune-stimulating saponin-lipid complexes
(iscoms).

ABSTRACT:
Immune-stimulating complexes (iscoms) are stable complexes of
cholesterol, phospholipid and Quil A, a triterpene saponin
mixture in the size range from 40 to 100 nm. They can be used as...

IDENTIFIERS: saponin; complex; structure; iscoms

16/3, K/15 (Item 4 from file: 24)
DI ALOG(R) File 24: CSA Life Sciences Abstracts
(c) 2009 CSA. All rights reserved.

0000894670 IP ACCESSION NO: 2209984
Immunogenicity of purified equine influenza virus HA and NA antigens.

van der Marel, P; Moeren, P; Verbruggen, W
Intervet Int. B.V., Postbox 31, 5830 AA Boxtmeer, Netherlands
EDITOR: Spier, RE; Griffiths, JB; Stephenne, J; Grooy, PJ (eds)

, p 521-525, 1989
ADDL. SOURCE INFO: ADVANCES IN ANIMAL CELL BIOLOGY AND TECHNOLOGY FOR
BIOPROCESSES., 1989, pp. 521-525
PUBLICATION DATE: 1989

CONFERENCE:
9. General Meeting of the European Society for Animal Cell Technology,
Knokke (Belgium), 1988

DOCUMENT TYPE: Book Monograph; Conference
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

ISBN: 0407014993

FILE SEGMENT: Biotechnology Research Abstracts; Immunology Abstracts;
Virology & AIDS Abstracts

ABSTRACT:

... presenting structures have been compared. It was found that a micellar preparation adjuvated with the saponin Quil A was equally immunogenic as more complex structures like iscoms and virosomes. The micellar preparation also induced high HI-titres in horses.

16/3, K/16 (Item 1 from file: 34)
DI ALOG(R) File 34: Sci Search(R) Cited Ref Sci
(c) 2009 The Thomson Corp. All rts. reserv.

05116473 Genuine Article#: VB495 No. References: 178
Title: SAPONINS AS VACCINE ADJUVANTS
Author: KENSIL OR
Corporate Source: CAMBRIDGE BIOTECH CORP, 365 PLANTAT ST/ WORCESTER/ MA/ 01605
Journal: CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1996, V13,
N1-2, P1-55
ISSN: 0743-4863
Language: ENGLISH Document Type: REVIEW (Abstract Available)

Abstract: Naturally occurring triterpene glycosides (saponins) from Quillaja saponaria have considerable adjuvant activity. Adjuvant functions include stimulation of high levels of antibody to...

...induction of cytotoxic T lymphocyte responses. This article reviews responses due to specific saponins or saponin preparations, effect of formulation, structure/function studies, and use in different preclinical and clinical vaccine...

... Descriptors: QUILLAJA SAPONARIA; ADJUVANT; VACCINE; QUILLAJA; QS-21

Research Fronts: 94-1576 005 (MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I GENES; PEPTIDE PRESENTATION; IMMUNE RECOGNITION; ANCHOR RESIDUES)

94-0437 001 (ANTI OXIDANT ACTIVITY; PEROXYL...

16/3, K/17 (Item 2 from file: 34)
DI ALOG(R) File 34: Sci Search(R) Cited Ref Sci
(c) 2009 The Thomson Corp. All rts. reserv.

04335322 Genuine Article#: RW618 No. References: 28
Title: COMPARISON OF ADJUVANTS FOR IMMUNE POTENTIATING PROPERTIES AND SIDE-EFFECTS IN MICE
Author: LEENAARS PPAM; HENDRIKSEN CFM; KOEDAM MA; CLAASSEN I; CLAASSEN E
Corporate Source: TNO, DIV INFECT DIS & IMMUNOL, POB 2215/2301 CE LEIDEN/ NETHERLANDS/; NATL INST PUBL HLTH & ENVIRONM PROTECT/ 3720 BA BILTHOVEN/ NETHERLANDS/; ERASMUS UNIV ROTTERDAM, DEPT IMMUNOL/ 3000 DR ROTTERDAM/ NETHERLANDS/
Journal: VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, V48, N1-2 (SEP), P123-138
ISSN: 0165-2427
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

... Abstract: Specol), a microorganism (Lactobacillus), performed immune-stimulating complexes (ISCOM) containing rabies virus glycoprotein and a saponin, Quil A. The adjuvants and saline were combined with three weak immunogens (a synthetic peptide, a ...

10562866.txt

...immunogens, Lesions were most severe after injection of antigen combined with Freund's adjuvant or Quil A, mild to moderate with Specol and minimal with Lactobacillus, iscom conjugates or saline. Despite...
...Identifiers: T-CELLS; DISTRESS; ISCOM; EXPERIENCE; COMPLEX; PAIN

16/3, K/18 (Item 3 from file: 34)
DIALOG(R) File 34: Sci Search(R) Cited Ref Sci
(c) 2009 The Thomson Corp. All rts. reserv.

00800422 Genuine Article#: EY222 No. References: 32
Title: EFFICACY OF PURIFIED ANAPLASMA-MARGINALE INITIAL BODIES AS A VACCINE AGAINST ANAPLASMOSIS
Author: MONTENEGRO JAMES S; JAMES MA; BENITEZ MT; LEON E; BAEK BK; GUILLEN AT
Corporate Source: TULANE UNIV, SCH PUBL HLTH & TROP MED, DEPT TROP MED, 1501 CANAL ST/ NEW ORLEANS/ LA 70112; FONAP, INST INVEST VET/ MARACAY/ VENEZUELA/; CHONBUK NATL UNIV, COLL VET MED/ CHONGJU/ SOUTH KOREA/
Journal: PARASITOLOGY RESEARCH, 1991, V77, N2, P93-101
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: 1.0 mg of solubilized Anaplasma protein. The immunogens were supplemented with 3.0 mg Quil-A saponin adjuvant and administered in 2 subcutaneous injections given at a 4-week interval. A similar...
...Identifiers: CATTLE; ADJUVANTS; IMMUNIZATION; ANTIGENS; ISOLATE; BOVINE; ANTIBODIES; PROTEINS; IMMUNITY; SAPONIN
...Research Fronts: BRAIN; AXOLININ LOCALIZATION
89-7196 001 (BABESIA-BOVIS PARASITES; MOLECULAR VACCINES; MSP-1 SURFACE PROTEIN COMPLEX INDUCES PROTECTION)

16/3, K/19 (Item 1 from file: 72)
DIALOG(R) File 72: EMBASE
(c) 2009 Elsevier B.V. All rts. reserv.

0083053893 EMBASE No: 2009288113
Immunology of TLR-independent vaccine adjuvants
De Gregorio E.; D'Oro U.; Wack A.
Novartis Vaccines and Diagnostics, 1 Via Fiorentina, 53100 Siena, Italy
AUTHOR EMAIL: ennio.de; gregorio@novartis.com
CORRESP. AUTHOR/ AFFIL: De Gregorio E.: Novartis Vaccines and Diagnostics, 1 Via Fiorentina, 53100 Siena, Italy
CORRESP. AUTHOR EMAIL: ennio.de; gregorio@novartis.com

Current Opinion in Immunology (Curr. Opin. Immunol.) (United Kingdom)
June 1, 2009, 21/3 (339-345)
CODEN: COPIE ISSN: 0952-7915
PUBLISHER ITEM IDENTIFIER: S0952791509000843
DOI: 10.1016/j.coi.2009.05.003
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 69

...at injection site followed by the differentiation of monocytes into activated DCs. The NLRP3 inflammasome complex is one of the molecular targets of particulate adjuvants and it is required for alum..

DRUG DESCRIPTORS:

...pharmaceutics--pr; n acetyl muramyl alanyl dextro isoglutamyl alanyl di palmitoyl phosphatidyl ethanolamine--pharmaceutics--pr; polyglactin --pharmaceutics--pr; polystyrene--pharmaceutics--pr; quil A

10562866.txt

--pharmaceutics--pr; saponin--pharmaceutics--pr; toll like receptor
agonist--pharmaceutics--pr
MEDICAL DESCRIPTORS:
accessory cell; cell activation; cell function; cell interaction; clinical
trial; complex formation; cross presentation; cytokine production;
dendritic cell; drug delivery system; drug mechanism; drug targeting;
emulsion...
...CAS REGISTRY NO.: 34346-01-5 (polyglactin); 9003-53-6 (polystyrene);
66594-14-7 (quil A); 8047-15-2 (saponin); 409141-78-2 (toll
like receptor)

16/3, K/20 (Item 2 from file: 72)
DIALOG(R) File 72: EMBASE
(c) 2009 Elsevier B.V. All rights reserved.

0082603648 EMBASE No: 2008387756

FML vaccine against canine visceral leishmaniasis: From second-generation
to synthetic vaccine

Palatnik-de-Sousa C.B.; Barbosa A.D.F.; Oliveira S.M.; Nico D.; Bernardo
R.R.; Santos W.R.; Rodrigues M.M.; Soares I.; Borja-Cabrera G.P.

OCS, UFRJ, Cidade Universitaria, Avda Carlos Chagas 373, Ilha do Fundao,
21941-590 Rio de Janeiro, Brazil; Instituto de Microbiologia, OCS, Cidade
Universitaria, Avda Carlos Chagas 373, Ilha do Fundao, 21941-590 Rio de
Janeiro, Brazil

AUTHOR EMAIL: imgcba@micro.ufrj.br; afb@oc.fiocruz.br;
smpveira@hotmail.com; dirlei@micro.ufrj.br; robson.roney@terra.com.br;
mrodrigues@cb.epm.br; isoares@usp.br; gulnara.borja@micro.ufrj.br

CORRESP. AUTHOR/AFFIL: Palatnik-de-Sousa C.B.: OCS, UFRJ, Cidade
Universitaria, Avda Carlos Chagas 373, Ilha do Fundao, 21941-590 Rio de
Janeiro, Brazil

CORRESP. AUTHOR EMAIL: imgcba@micro.ufrj.br

Expert Review of Vaccines (Expert Rev. Vaccines) (United Kingdom)
August 1, 2008, 7/6 (833-851)

CODEN: ERVXA ISSN: 1476-0584 eISSN: 1744-8395

DOI: 10.1586/14760584.7.6.833

URL: <http://www.expert-reviews.com/doi/pdf/10.1586/14760584.7.6.833>

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 138

...92-95% of protection and 76-80% of vaccine efficacy) when formulated
with a QS21 saponin-containing adjuvant. It became the licensed
Leishmune(R) vaccine for canine prophylaxis in Brazil. The...

...the incidence of the human and canine disease. A 36-kDa glycoprotein, in
the FML complex, is the human marker of the disease, which was
protective in mice as native recombinant...

...tested against the canine disease. This review resumes the development
of the second-generation FML-saponin-Leishmune vaccine, its adjuvant
and of the NH36 DNA vaccine, toward the identification of its...

DRUG DESCRIPTORS:

...*dv; *Leishmania vaccine--drug development--dv; *Leishmania vaccine
--drug therapy--dt; *Leishmania vaccine--pharmaceutics--pr; *quil A
--drug combination--cb; *quil A--drug development--dv; *quil A
--drug therapy--dt; *quil A--intraperitoneal drug administration--ip
...endogenous compound--ec; qs 21--drug development--dv; qs 21--drug
therapy--dt; recombinant protein; saponin--drug development--dv;
saponin derivative; unclassified drug; indexed drug

MEDICAL DESCRIPTORS:

10562866.txt

... DRUG TERMS (UNCONTROLLED): antigen--drug combination--cb; fucose mannose ligand antigen--drug development--dv; fucose mannose ligand antigen saponin r vaccine--drug development--dv; fucose mannose ligand antigen saponin r vaccine--drug therapy--dt; fucose mannose ligand antigen saponin r vaccine--intraperitoneal drug administration--ip; fucose mannose ligand antigen saponin r vaccine--pharmaceutics--pr; fucose mannose ligand antigen saponin r vaccine--subcutaneous drug administration--sc; glycoprotein gp 36--drug development--dv; glycoprotein gp 36...

... lack antigen--drug development--dv; lack antigen--drug therapy--dt; leishmune; recombinant glycoprotein gp 63; saponin cp 05--drug development--dv; saponin cp 05--drug therapy--dt; saponin r --drug combination--cb; saponin r--drug development--dv; saponin r--drug therapy--dt; transmission blocking vaccine
... CAS REGISTRY NO.: cysteine proteinase); 138415-13-1 (interleukin 12); 141256-04-4 (qs 21); 66594-14-7 (quil A); 8047-15-2 (saponin)

16/3, K/21 (Item 3 from file: 72)
DI ALOG(R) File 72: EMBASE
(c) 2009 Elsevier B.V. All rights reserved.

0081854408 EMBASE No: 2007288555
Cell-mediated immune responses induced by BHV-1: Rational vaccine design
Van Drunen Littell-Van Den Hurk S.
University of Saskatchewan, Vaccine and Infectious Disease Organization,
120 Veterinary Rd., Saskatoon, Sask. S7N 5E3, Canada
AUTHOR EMAIL: sylvia.vandenhurk@sask.ca
CORRESP. AUTHOR/AFFIL: Van Drunen Littell-Van Den Hurk S.: University of
Saskatchewan, Vaccine and Infectious Disease Organization, 120 Veterinary
Rd., Saskatoon, Sask. S7N 5E3, Canada
CORRESP. AUTHOR EMAIL: sylvia.vandenhurk@sask.ca

Expert Review of Vaccines (Expert Rev. Vaccines) (United Kingdom) June
1, 2007, 6/3 (369-380)
CODEN: ERVXA ISSN: 1476-0584 eISSN: 1744-8395
DOI: 10.1586/14760584.6.3.369
URL: <http://www.future-drugs.com/doi/pdf/10.1586/14760584.6.3.369>
DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 97

DRUG DESCRIPTORS:

...pr; protein C--drug development--dv; protein C--drug therapy--dt;
protein C--pharmacology--pd; quil A--drug development--dv; quil
A--pharmacology--pd; saponin--pharmaceutics--pr; T lymphocyte
receptor--endogenous compound--ec; unindexed drug; virus DNA; virus vector
--pharmaceutics...

MEDICAL DESCRIPTORS:

...animal comparison; humoral immunity; immunological memory;
immunomodulation; lower respiratory tract infection--etiology--et; major
histocompatibility complex; memory T lymphocyte; nonhuman; priority
journal; review; seroconversion; seroprevalence; T cell depletion; T
lymphocyte subpopulation...
... CAS REGISTRY NO.: interleukin 12); 85898-30-2 (interleukin 2);
60202-16-6 (protein C); 66594-14-7 (quil A); 8047-15-2 (saponin)

16/3, K/22 (Item 4 from file: 72)
DI ALOG(R) File 72: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0080319204 EMBASE No: 2004505031

ISCOMATRIX(R) adjuvant for antigen delivery

Pearse M.J.; Drane D.

Research and Development, CSL Limited, 45 Poplar Rd., Parkville 3052, A.

AUTHOR EMAIL: martin.pearse@sl.com.au

CORRESP. AUTHOR/AFFIL: Research and Development, CSL Limited, 45 Poplar Rd., Parkville 3052, A.

CORRESP. AUTHOR EMAIL: martin.pearse@sl.com.au

Advanced Drug Delivery Reviews (Adv. Drug Deliv. Rev.) (Netherlands)

January 10, 2005, 57/3 SPEC. ISS. (465-474)

CODEN: ADDRE ISSN: 0169-409X

PUBLISHER ITEM IDENTIFIER: S0169409X04002133

DOI: 10.1016/j.addr.2004.09.006

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 32

The immunostimulating complex, referred to as 'iscom', was first described by Morein et al. in 1984 as a...
...both MHC class I and class II pathways, and the powerful immunomodulatory capability of the saponin. Additionally, the ISCOMATRIX(R) adjuvant is simple to manufacture and can be combined with a...

BRAND NAME/ MANUFACTURER NAME: ISCOM; iscomatrix; iscoprep; qs 21; quil A

DRUG DESCRIPTIONS:

...therapy--dt; qs 21--drug toxicity--to; qs 21--pharmaceutics--pr; qs 21--pharmacology--pd; quil A--clinical trial--ct; quil A--drug combination--cb; quil A--pharmaceutics--pr; saponin--adverse drug reaction--ae; saponin--clinical trial--ct; saponin--drug combination--cb; saponin--drug development--dv; saponin--drug dose--do; saponin--drug therapy--dt; saponin--drug toxicity--to; saponin--pharmaceutics--pr; saponin--pharmacology--pd; unclassified drug; vaccine--clinical trial--ct; vaccine--pharmaceutics--pr; vaccine--pharmacology--pd; virus...

MEDICAL DESCRIPTIONS:

...humoral immunity; hydrophobicity; immunomodulation; immunostimulation; immunotherapy; Influenza virus; injection pain--side effect--si; major histocompatibility complex; nonhuman; pain--side effect--si; priority journal; Quillaja; review; side effect--side effect--si; skin induration--side effect--si; structure activity relation; tumor...

... DRUG TERMS (UNCONTROLLED): clinical trial--ct; ny eso 1 vaccine--pharmaceutics--pr; ny eso 1 vaccine--pharmacology--pd; quillaja saponaria extract--adverse drug reaction--ae; quillaja saponaria extract--drug combination--cb; quillaja saponaria extract--drug development--dv; quillaja saponaria extract--drug dose--do; quillaja saponaria extract--drug therapy--dt; quillaja saponaria extract--drug toxicity--to; quillaja saponaria extract--pharmaceutics--pr; quillaja saponaria extract--pharmacology--pd
... CAS REGISTRY NO.: dipalmitoylphosphatidylcholine; 88598-53-2 (phosphoryl lipid A); 141256-04-4 (qs 21); 66594-14-7 (quil A); 8047-15-2 (saponin)

16/3, K/23 (Item 5 from file: 72)

DI ALOG(R) File 72: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0078706811 EMBASE No: 2001313142

10562866.txt

Different respiratory syncytial virus and Quillaja saponin formulations induce murine peritoneal cells to express different proinflammatory cytokine profiles

Hu K.-F.; Chen M.; Abusugra I.; Monaco F.; Morein B.

Faculty of Veterinary Medicine, Department of Veterinary Microbiology, Swedish University of Agricultural Sciences, S-751 23 Uppsala, Sweden

AUTHOR EMAIL: kefei.hu@mc.uu.se

CORRESP. AUTHOR/AFFIL: Hu K.-F.: Faculty of Veterinary Medicine, Department of Veterinary Microbiology, Swedish Univ. of Agricultural Sci., S-751 23 Uppsala, Sweden

CORRESP. AUTHOR EMAIL: kefei.hu@mc.uu.se

FEMS Immunology and Medical Microbiology (FEMS Immunol. Med. Microbiol.) (Netherlands) September 18, 2001, 31/2 (105-112)

CODEN: FIME ISSN: 0928-8244

PUBLISHER ITEM IDENTIFIER: S0928824401002516

DOI: 10.1016/S0928-8244(01)00251-6

DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 32

Different respiratory syncytial virus and Quillaja saponin formulations induce murine peritoneal cells to express different proinflammatory cytokine profiles

...capacity to provoke cultured murine peritoneal cells to produce these three proinflammatory cytokines. RSV immunostimulating complex (ISCOM), i.e. both antigen and adjuvant are incorporated in the same particle, induced high...

...was earlier than for the other antigen formulations containing corresponding doses of antigen and/or Quillaja adjuvant. Peak values for production of TNF-alpha and IL-6 were at 8 h...

DRUG DESCRIPTORS:

...*pr; *immunological adjuvant--pharmacology--pd; *ISCOM--drug comparison--cm; *ISCOM--pharmaceutics--pr; *ISCOM--pharmacology--pd; *quill A--drug comparison--cm; *quill A--pharmaceutics--pr; *quill A--pharmacology--pd; *respiratory syncytial virus vaccine--pharmaceutics--pr; *respiratory syncytial virus vaccine--pharmacology--pd

MEDICAL DESCRIPTORS:

CAS REGISTRY NO.: 66594-14-7 (quill A)

16/3, K/24 (Item 6 from file: 72)

DIALOG(R) File 72: EMBASE

(c) 2009 Elsevier B.V. All rights reserved.

0077571903 EMBASE No: 1999058034

Oral vaccination with immune stimulating complexes

McI Mowat A.; Smith R.E.; Donachie A.M.; Furrie E.; Grdic D.; Lycke N. Department of Immunology, Univ. Glasgow, W Infirm., G., Glasgow, United Kingdom

AUTHOR EMAIL: a.m.mowat@clinmed.gla.ac.uk

CORRESP. AUTHOR/AFFIL: Mowat A.M.: Department of Immunology, University of Glasgow, Western Infirmary, Glasgow G11 6NT, United Kingdom

CORRESP. AUTHOR EMAIL: a.m.mowat@clinmed.gla.ac.uk

Immunology Letters (Immunol. Lett.) (Netherlands) January 1, 1999, 65/1-2 (133-140)

CODEN: IMLEED ISSN: 0165-2478

PUBLISHER ITEM IDENTIFIER: S0165247898001369

DOI: 10.1016/S0165-2478(98)00136-9

DOCUMENT TYPE: Journal; Conference Paper RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 33

... purified antigens. Here we describe our experience with lipophilic immune stimulating complexes (ISCOMs) containing the saponin adjuvant Quil A. When given orally, ISCOMs containing the model protein antigen ovalbumin (OVA) induce a wide...

DRUG DESCRIPTORS:

*quil a--pharmacology--pd; *vaccine--drug development--dv; *vaccine--pharmacology--pd

MEDICAL DESCRIPTORS:

animal experiment; antigen antibody complex; conference paper; controlled study; cytotoxic T lymphocyte; immunogenicity; immunostimulation; mouse; nonhuman; oral drug administration; priority...

CAS REGISTRY NO.: 10102-43-9 (nitric oxide); 77466-29-6 (ovalbumin); 66594-14-7 (quil A)

16/3, K/25 (Item 7 from file: 72)
DI ALOG(R) File 72: EMBASE
(c) 2009 Elsevier B.V. All rights reserved.

0077504464 EMBASE No: 1998414931

ISCOMs: An adjuvant with multiple functions

Sjolander A.; Cox J.C.; Barr I.G.

Immunology Department, CSL Limited, Melbourne, Vic., Australia;

Immunology Department, CSL Limited, 45 Poplar Road, Melbourne, Vic. 3052, Australia

AUTHOR EMAIL: asjoland@csll.com.au

CORRESP. AUTHOR/AFFIL: Sjolander A.: Immunology Department, CSL Limited, 45 Poplar Road, Melbourne, Vic. 3052, Australia

CORRESP. AUTHOR EMAIL: asjoland@csll.com.au

Journal of Leukocyte Biology (J. Leukocyte Biol.) (United States)

December 1, 1998, 64/6 (713-723)

CODEN: JLBIE ISSN: 0741-5400

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

NUMBER OF REFERENCES: 152

... ability to induce a broad range of immune responses, including cell-mediated immunity. The immunostimulating complex or ISCOM is one adjuvant with multiple adjuvant properties. ISCOMs are open cage-like complexes...

... are built up by cholesterol, lipid, immunogen, and saponins from the bark of the tree Quillaja saponaria Molina. ISCOMs have been demonstrated to promote antibody responses and induce T helper cell...

DRUG DESCRIPTORS:

... *adjuvant--pharmaceutics--pr; *iscom--adverse drug reaction--ae; *iscom--clinical trial--ct; *iscom--pharmaceutics--pr; *quil a; *vaccine--clinical trial--ct; *vaccine--pharmaceutics--pr

... keyhole limpet hemocyanin; liposome; major histocompatibility antigen class 2--endogenous compound--ec; microsphere; ovalbumin; phospholipid; saponin--adverse drug reaction--ae; saponin--clinical trial--ct; tumor vaccine--adverse drug reaction--ae; tumor vaccine--clinical trial--ct; tumor...

MEDICAL DESCRIPTORS:

... CAS REGISTRY NO.: 88-5 (cholesterol); 19600-01-2 (ganglioside GM2); 77466-29-6 (ovalbumin); 66594-14-7 (quil A); 8047-15-2 (saponin)

16/3, K/26 (Item 8 from file: 72)
 DI ALOG(R) File 72: EMBASE
 (c) 2009 Elsevier B.V. All rights reserved.

0076286971 EMBASE No: 1995321063

Adjuvants for human vaccines. Current status, problems and future prospects

Gupta R. K.; Siber G. R.

MA Public Health Biologic Labs., State Laboratory Institute, Boston, MA 02130, United States

CORRESP. AUTHOR/ AFFIL: Gupta R. K.: MA Public Health Biologic Labs., State Laboratory Institute, Boston, MA 02130, United States

Vaccine (VACCINE) (United Kingdom) November 22, 1995, 13/14 (1263-1276)

CODEN: VACOD ISSN: 0264-410X

DOI: 10.1016/0264-410X(95)00011-O

DOCUMENT TYPE: Journal; Review RECORD TYPE: Abstract

LANGUAGE: English SUMMARY LANGUAGE: English

...response. With the use of adjuvants immune response can be selectively modulated to major histocompatibility complex (MHC) class I or MHC class II and Th1 or Th2 type, which is very...

DRUG DESCRIPTIONS:

...inulin; iscom lipopolysaccharide; monoclonal antibody; murabutide; muramyl dipeptide; n-acetylmuramylalanyl dextroisoglutaminylalanyldipalmitoylphosphatidylethanolamine; qs 21; quil A; saponin; tetanus toxoid

MEDICAL DESCRIPTIONS:

...CAS REGISTRY NO.: 56-7 (n-acetylmuramylalanyl dextroisoglutaminylalanyldipalmitoylphosphatidylethanolamine); 141256-04-4 (qs 21); 66594-14-7 (quil A); 8047-15-2 (saponin); 57425-69-1...

16/3, K/27 (Item 9 from file: 72)
 DI ALOG(R) File 72: EMBASE
 (c) 2009 Elsevier B.V. All rights reserved.

0075440118 EMBASE No: 1993219674

Vaccine delivery systems: Potential methods for use in antifertility vaccines

Stevens V. C.

Department of Obstetrics/Gynecology, Ohio State University, 1654 Upham Drive, Columbus, OH 43210, United States

CORRESP. AUTHOR/ AFFIL: Stevens V. C.: Department of Obstetrics/Gynecology, Ohio State University, 1654 Upham Drive, Columbus, OH 43210, United States

American Journal of Reproductive Immunology (AM J. REPROD. IMMUNOL.) (Denmark) August 13, 1993, 29/3 (176-188)

CODEN: AAJID ISSN: 8755-8920

DOCUMENT TYPE: Journal; Review RECORD TYPE: Citation

LANGUAGE: English

DRUG DESCRIPTIONS:

...microsphere; oil--drug administration--ad; oil--pharmaceuticals--pr; polymer--drug administration--ad; polymer--pharmaceuticals--pr; quil A--drug administration--ad; quil A--drug dose--do; quil A--pharmaceuticals--pr; saponin--drug administration--ad; saponin--pharmaceuticals--pr

MEDICAL DESCRIPTIONS:

10562866.txt

... presentation; cloning vector; drug administration; emulsion; human;
immunity; immunogenicity; immunostimulation; intramuscular drug
administration; major histocompatibility complex; nonhuman;
pharmaceuticals; priority journal; review; salmonella; vaccinia virus
CAS REGISTRY NO.: 9007-81-2 (Freund adjuvant); 66594-14-7 (quill A);
8047-15-2 (saponin)

16/3, K/28 (Item 1 from file: 73)
DI ALOG(R) File 73: EMBASE
(c) 2009 Elsevier B.V. All rights reserved.

0075093005 EMBASE No: 1992244678
Adjuvant activity and ISCOM formation by structurally diverse saponins
Bomford R.; Stapleton M.; Wnsor S.; Beesley J. E.; Jessup E. A.; Price
K. R.; Fenwick G. R.
Institut Pasteur, Un. d' Epidemiol. des Virus Oncogenes, 28 Rue du Dr.
Roux, 75724 Paris Cedex 15, France
CORRESP. AUTHOR/ AFFIL: Bomford R.: Institut Pasteur, Un. d' Epidemiol. des
Virus Oncogenes, 28 Rue du Dr. Roux, 75724 Paris Cedex 15, France

Vaccine (VACCINE) (United Kingdom) August 25, 1992, 10/9 (572-577)
CODEN: VACOD ISSN: 0264-410X
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English

Adjuvant activity and immunostimulating complex (ISCOM) formation
by a series of saponins and glycoalkaloids differing in the structures of
their aglycones and sugar chains were examined. The only two saponins apart
from Quillaja that were adjuvant-active were Gypsophila and
Saponaria, which resemble Quillaja in that they contain saponins with
branched sugar chains attached to positions 3 and 28...
...like structures, and Gypsophila produced a sheet of joined pore-like
structures. The alfalfa hederagenin saponin and Quinoa also formed
pore-sheets, despite lacking adjuvant activity.

BRAND NAME/ MANUFACTURER NAME: quill a/ super fos/ Denmark

DRUG DESCRIPTORS:

... *drug development--dv; *alkaloid--pharmacology--pd; *immunological
adjuvant--drug development--dv; *immunological adjuvant--pharmacology--pd;
*saponin--drug comparison--cm; *saponin--drug development--dv;
*saponin--pharmacology--pd
glycyrrhizic acid--drug comparison--cm; glycyrrhizic acid--pharmacology--pd
; quill a--drug comparison--cm; quill a--pharmacology--pd;
unclassified drug

MEDICAL DESCRIPTORS:

CAS REGISTRY NO.: 1405-86-3 (glycyrrhizic acid); 66594-14-7 (quill A);
8047-15-2 (saponin); 78693-94-4 (soyasaponin a1)

16/3, K/29 (Item 1 from file: 144)
DI ALOG(R) File 144: Pascal
(c) 2009 INIST/CNRS. All rights reserved.

14684093 PASCAL No.: 00-0358239
Preparation and characterisation of quillaja saponin with
less heterogeneity than Quill-A
KAMSTRUP S.; SAN MARTIN R.; DOBERTI A.; GRANDE H.; DALSGAARD K.
Danish Veterinary Institute for Virus Research, Lindholm, 4771, Kalvehave
, Denmark; Catholic University, Department of Chemical Engineering, Av.
Vicuna Mackenna 4860, Santiago, Chile; Licentech, Bernadottelaan 15, P. O.
Box 8323, 3503 RH, Utrecht, Netherlands
Journal: Vaccine, 2000, 18 (21) 2244-2249

Language: English

Copyright (c) 2000 INIST-CNRS. All rights reserved.

Preparation and characterisation of quillaja saponin with less heterogeneity than Quil-A

... are most often required to obtain satisfactory immune responses. One such type of adjuvant is saponin derived from the bark of Quillaja saponaria Molina, a tree of the rose family. A few different commercial sources exist, but due to the structural complexity and heterogeneity of these saponin preparations, it has been difficult to establish exactly which components are responsible for the adjuvant... selecting the bark source, we have succeeded in preparing a much less heterogeneous preparation of quillaja saponin. In this report we describe the preparation, in terms of structural complexity, hemolytic activity, adjuvant...

English Descriptors: Vaccine; Immunological adjuvant; Saponin; Plant origin; Biological activity; Hemolysis; Immunostimulation; Immunostimulating complex

French Descriptors: Vaccine; Adjuvant immunologique; Saponine; Origine végétale; Activité biologique; Hémolysé; Immunostimulation; Quil A; Quillaja saponaria; Complexe ISCOM

16/3, K/30 (Item 2 from file: 144)
DI ALOG(R) File 144: Pascal
(c) 2009 INIST-CNRS. All rights reserved.

13711969 PASCAL No.: 98-0403050
Studies on experimental adjuvanted influenza vaccines : Comparison of immune stimulating complexes (Iscoms SUP T SUP M) and oil-in-water vaccines
COULTER A; WONG T Y; DRANE D; BATES J; MACFARLAN R; COX J
CSL Limited, 45 Poplar Road, Parkville, Victoria 3052, Australia
Journal: Vaccine, 1998, 16 (11-12) 1243-1253
Language: English

Copyright (c) 1998 INIST-CNRS. All rights reserved.

...differences were observed between the adjuvant formulations. Iscom SUP T SUP M vaccines, formulated with Quil-A or the less toxic Quillaja saponin preparation Iscoprep SUP T SUP M 703, induced specific cytotoxic T-lymphocyte responses, whereas the...

English Descriptors: Influenzavirus A; Mouse; Vaccine; Immunogenicity; Immunological adjuvant; Property formulation relationship; Oil water emulsion; Immunostimulating complex

16/3, K/31 (Item 1 from file: 154)
DI ALOG(R) File 154: MEDLINE(R)
(c) format only 2009 Dialog. All rights reserved.

18059238 PMID: 17722580
[Elaboration of new adjuvant lipid-saponin complex and its use at experimental immunization by bacterial antigen]
Tsybul'skii A V; Sanina N M; Li I A; Popov A M; Kostetski E I a; Portnagina O I u; Shnyrov V L
Biomeditsinskai a khimi a (Russia (Federation)) May-Jun 2007, 53
(3) p297-306, Journal Code: 101196966
Publishing Model Print

10562866.txt

Document type: English Abstract; Journal Article

Languages: RUSSIAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

[Elaboration of new adjuvant lipid-saponin complex and its use at experimental immunization by bacterial antigen]

... matrix by the replacement of the phospholipid for the glycolipid (monogalactosyl diacylglycerol) from sea macrophytes, and saponin Quil A to triterpene glycoside of cucumarioside A2-2 from Cucumaria japonica are shown. The resultant complexes...

Chemical Name: Adjuvants, Immunologic; Antibodies; Antigens, Bacterial; Galactolipids; Phosphatidylcholines; Porins; Saponins; Triterpenes; monogalactosyl diacylglycerol; Quil A; cucumarioside

16/3, K/32 (Item 1 from file: 162)

DI ALOG(R) File 162: Global Health

(c) 2009 CAB International. All rights reserved.

0004414383 CAB Accession Number: 19912083200

Viral vaccines.

Advances in Biotechnological Processes. vol. 14 xiv + 381 pp.

Publication Year: 1990

Editors: Mzrahi, A.

ISBN: 0-471-56782-5

Language: English

Record Type: Abstract

Document Type: Book

... viral membrane is mimicked and the immunodominant epitopes that stimulate immunity are exposed. This immunosome complex is free from nucleic acid and protein of cellular origin and only contains relevant antigen...

... or Iscoms. The latter consist of antigen attached to an adjuvant matrix consisting of the saponin Quil A and lipid, producing a highly immunogenic complex for reasons that are not yet clear. Insect cell cultures offer the possibility of foreign...

16/3, K/33 (Item 1 from file: 399)

DI ALOG(R) File 399: CA SEARCH(R)

(c) 2009 American Chemical Society. All rights reserved.

149371103 CA: 149(17)371103x PATENT

Fertility regulation in horses using an adjuvant composition (comprising an anionic macromol. component and a saponin) and an immunogen

INVENTOR(AUTHOR): Si bert, Gary J.

LOCATION: USA

ASSIGNEE: Pfizer, Inc.

PATENT: PCT International ; WO 2008110912 A1 DATE: 20080918

APPLICATION: WO 2008110912 A1 (20080305) *US 2007PV918179 (20070314)

PAGES: 48pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

IPC Class. B6D 1/00 + Level Value Position Status Version Action Source Office:

A61K 0039/39

A I F B 20060101

H EP

DESIGNATED COUNTRIES: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BG; BH; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DO; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LY; MA; MD; ME; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG;

10562866.txt

SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT DESIGNATED REGIONAL: AT; BE; BG; CH
; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LT; LU; LV;
MC; MT; NL; NO; PL; PT; RO; SE; SI; SK; TR; BF; BJ; OF; OG; CI; CM; GA; GN;
GQ; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ;
TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

16/3, K/34 (Item 2 from file: 399)
DIALOG(R) File 399: CA SEARCH(R)
(c) 2009 American Chemical Society. All rights reserved.

117046550 CA: 117(5)46550s PATENT
Immunogenic complexes, in particular iscoms, containing Quil A fractions
INVENTOR(AUTHOR): Kersten, Gideon Frank Anne; Spijkstra, Arjen; Van de
Werken, Gerrit; Beuvery, Eduard Coen
LOCATION: Neth.
ASSIGNEE: De Staat der Nederlanden Vertegenwoordigd Door de Minister Van
Welzijn Volksgezondheid en Cultuur
PATENT: PCT International ; WO 9206710 A1 DATE: 920430
APPLICATION: WO 91NL211 (911023) *NL 902314 (901023)
PAGES: 40 pp. CODEN: PIXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: A61K-039/39A; C07H-015/256B; A61K-039/385B
DESIGNATED COUNTRIES: CA; US DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES
; FR; GB; GR; IT; LU; NL; SE

16/3, K/35 (Item 1 from file: 35)
DIALOG(R) File 35: Dissertation Abs Online
(c) 2009 ProQuest Info&Learning. All rights reserved.

0996599 ORDER NO: NOT AVAILABLE FROM UNIVERSITY MICROFILMS INT'L.
CONSTRUCTION AND POTENTIAL OF THE ISCOM AS IMMUNOGEN (QUIL A,
SAPONIN, VACCINE)
Author: LOVGREN, KARI N
Degree: FIL.
Year: 1987
Corporate Source/Institution: SVERIGES LANTBRUKSUNIVERSITET (SWEDEN) (
0697)
Source: VOLUME 49/01- C OF DISSERTATION ABSTRACTS INTERNATIONAL.
PAGE 63. 52 PAGES
ISBN: 91-576-3202-2
Publisher: SVERIGES LANTBRUKSUNIVERSITET, S-750 07 UPPSALA, SWEDEN

CONSTRUCTION AND POTENTIAL OF THE ISCOM AS IMMUNOGEN (QUIL A,
SAPONIN, VACCINE)

The iscom-immunostimulating complex--is a highly immunogenic
formulation of microbial membrane antigens. The adjuvant Quil A forms
together with cholesterol a matrix into which amphipathic molecules are
incorporated by hydrophobic...

16/3, K/36 (Item 1 from file: 357)
DIALOG(R) File 357: Derwent Biotech Res.
(c) 2009 Thomson Reuters. All rights reserved.

0465554 DBR Accession No.: 2009-11190 PATENT
New vaccine composition comprises immune stimulating complex,
saccharide antigen and aluminum containing adjuvant, used for preparing
medicament for treating clinical condition, e.g. bacteremia,
meningitis, and pneumonia, in an individual - pharmaceutical
composition comprising immune stimulating complex, saccharide

antigen and aluminum containing adjuvant, useful as vaccine for treatment and prevention of bacteraemia, meningitis and pneumonia

AUTHOR: KIRKBY N S; SCHIOTT A

PATENT ASSIGNEE: NORDIC VACCINE AS 2009

PATENT NUMBER: WO 2009106085 PATENT DATE: 20090903 WPI ACCESSION NO.: 2009-N26027 (200961)

PRIORITY APPLIC. NO.: DK 2008691 APPLIC. DATE: 20080519

NATIONAL APPLIC. NO.: WO 2009DK50047 APPLIC. DATE: 20090227

LANGUAGE: English

New vaccine composition comprises immune stimulating complex, saccharide antigen and aluminum containing adjuvant, used for preparing medicament for treating clinical condition, e.g. bacteraemia, meningitis, and pneumonia, in an individual - pharmaceutical composition comprising immune stimulating complex, saccharide antigen and aluminum containing adjuvant, useful as vaccine for treatment and prevention of bacteraemia...

ABSTRACT: DERVENT ABSTRACT: NOVELTY - A vaccine composition comprising: (a) an immune stimulating complex comprising at least one saponin, and at least one sterol, and at least one contacting group capable of binding a nucleic acid, where contacting group may be covalently attached to at least one saponin or to at least one sterol or to at least one lipophilic moiety, the complex being associated with at least one carrier protein designated carrier protein A; (b) at least...

... is infection by microbial organisms. BIOTECHNOLOGY - Preferred Vaccine: In the vaccine above, the immune stimulating complex further comprises a lipophilic moiety. The contacting group is capable of binding a nucleic acid via electrostatic or hydrophobic interactions. It is a cationic moiety. The at least one saponin is selected from synthetic saponins and naturally occurring saponins. Preferably, the at least one saponin is selected from saponins comprising a triterpene glycoside, saponins comprising a steroid glycoside, and saponins comprising a steroid alkaloid glycoside; or the at least one saponin comprises a triterpene glycoside comprising an aglycone compound and a saccharide compound. The at least one saponin comprises a triterpene glycoside isolated from a Quillaja plant species. Specifically, the at least one saponin is isolated from Quillaja saponaria species. The at least one saponin is isolated from Quillaja saponaria molina or Quillaja saponaria officinalis. Additionally, the at least one saponin is Quillajabark Araloside A (Quil A). The at least one saponin comprises at least one saponin selected from QA-7 (QS-7), QA-17 (QS-17), QA-18 (QS-18) and...

... least one sterol is selected from synthetic sterols and naturally occurring sterols. The immune stimulating complex comprises at least two different sterols. At least one sterol is selected from sterols comprising...

... diol eoyle-3-trimethylammoniumpropane-cholesterol (DC)-cholesterol and total cholesterol (TC)-cholesterol. The immune stimulating complex comprises at least two different sterols. The carrier protein A or B is selected from...

... to carrier protein B. Preferably, the carrier protein A is incorporated into the immune stimulating complex. The at least one saccharide antigen is derived from a microbial organism. It is derived...

... and aluminum hydroxide. The vaccine composition comprises aluminum containing adjuvant to which the immune stimulating complex associated with carrier protein A and the saccharide antigen attached

to the carrier protein B...

DESCRIPTORS: pharmaceutical comp., immune stimulating complex, saccharide antigen, aluminium containing adjuvant, appl., vaccine, bacteraemia, meningitis, pneumonia therapy, prevention neurprotective virucide antiinflammatory...

16/3, K/37 (Item 2 from file: 357)

DI ALOG(R) File 357: Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0460947 DBR Accession No.: 2009-06388 PATENT

New active composition comprising an RNA encoding antigens, useful for preparing a vaccine for the treatment of lung cancer, preferably of a non-small-cell lung cancer (NSCLC) related condition, e.g. squamous cell lung carcinoma - pharmaceutical composition comprising antigen obtained by RNA expression, useful as nucleic acid vaccine for prevention of cancer

AUTHOR: BARNER M; HOERR I; LANDER T; PROBST J

PATENT ASSIGNEE: CUREVAC GMBH 2009

PATENT NUMBER: WO 200946738 PATENT DATE: 20090416 WPI ACCESSION NO.:

2009-H35783 (200932)

PRIORITY APPLIC. NO.: WO 2007EP008770 APPLIC. DATE: 20071009

NATIONAL APPLIC. NO.: WO 2007EP8770 APPLIC. DATE: 20071009

LANGUAGE: English

... ABSTRACT: P1205); cytokine-containing liposomes; dimethyl dioctadecyl ammonium bromide (DDA); dehydroepiandrosterone (DHEA); dimyristoyl phosphatidylcholine (DMPC); dimyristoyl phosphatidylglycerol (DMPG); DOG/aluminum complex (deoxycholic acid sodium salt); Freund's complete adjuvant; Freund's incomplete adjuvant; gamma inulin; Gerbu...

... acetylmuramyl-L-alanyl-D-glutamine (GMDP); (ii) dimethyl dioctadecyl ammonium chloride (DDA); (iii) zinc-L-proline salt complex (ZnPro-8); granulocyte macrophage-colony stimulating factor (GM-CSF); N-acetylglucosaminyl-(b1-4)-N-acetyl muramyl...

... L121; polymethyl methacrylate (PMMA); PODDS(RTM proteinoid microspheres); polyethylene carbamate derivatives; polyadenylic acid-polyuridylic acid complex (poly-rA:poly-rU); polysorbate 80 (Tween 80); protein cochleates (Avanti Polar Lipids, Inc., Alabaster, AL); STIMULON(RTM QS-21); Quil-A (Quil-A saponin); S-28463 (4-amino-otoc-dimethyl-2-ethoxymethyl-1H-imidazo(4,5-c)quinolin-1-yl...

... CRL1005), L121, Poloxamer 4010), etc.; liposomes, including Stealth, cochleates, including BIORAL; plant derived adjuvants, including QS21, Quil A, Iscomatrix, ISCOM; adjuvants suitable for costimulation including Tomatine, biopolymers, including PLG, PMM, Inulin; microbe...

16/3, K/38 (Item 3 from file: 357)

DI ALOG(R) File 357: Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0460944 DBR Accession No.: 2009-06385 PATENT

New active composition comprising an RNA, useful for preparing a vaccine for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related to it - recombinant protein produced by vector mediated gene expression in host cell, useful as vaccine for prevention of cancer

AUTHOR: HOERR I; LANDER T; PROBST J

PATENT ASSIGNEE: CUREVAC GMBH 2009

PATENT NUMBER: WO 200946739 PATENT DATE: 20090416 WPI ACCESSION NO.:

2009- H35412 (200932)

PRIORITY APPLIC. NO.: WO 2007EP008771 APPLIC. DATE: 20071009

NATIONAL APPLIC. NO.: WO 2007EP8771 APPLIC. DATE: 20071009

LANGUAGE: English

... ABSTRACT: P1205); cytokine-containing liposomes; dimethyldioctadecyl ammonium bromide (DDA); dehydroepiandrosterone (DHEA); dimyristoylphosphatidylcholine (DMPC); dimyristoylphosphatidylglycerol (DMPG); DOG/alum complex (deoxycholic acid sodium salt); Freund's complete adjuvant; Freund's incomplete adjuvant; gamma inulin; Gerbu...

... acetylmuramyl-L-alanyl-D-glutamine (GMDP); (ii) dimethyldioctadecyl ammonium chloride (DDA); (iii) zinc-L-proline salt complex (ZnPro-8); granulocyte macrophage-colony stimulating factor (GM-CSF); N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl...

... L121; polymethyl methacrylate (PMMA); PODDS(RTM proteinoid microspheres); polyethylene carbamate derivatives; polyadenylic acid-polyuridylic acid complex (poly-rA:poly-rU); polysorbate 80 (Tween 80); protein cochleates (Avanti Polar Lipids, Inc., Alabaster, AL); STIMULON(RTM QS-21); Quil-A (Quil-A saponin); S-28463 (4-amino-otoc-diethyl-2-ethoxymethyl-1H-imidazo(4,5-c)quinoline-1...

... CRL1005), L121, Poloxamer 4010), etc.; liposomes, including Stealth, cochleates, including BIORAL; plant derived adjuvants, including QS21, Quil A, Iscomatrix, ISCOM adjuvants suitable for costimulation including Tomatine, biopolymers, including PLG, PM, Inulin; microbe...

16/3, K/39 (Item 4 from file: 357)

DI ALOG(R) File 357: Derwent Biotech Res.

(c) 2009 Thomson Reuters. All rights reserved.

0452386 DBR Accession No.: 2008-10895 PATENT

Use of a base-modified RNA sequence for increasing protein expression and preparation of a pharmaceutical composition for treating cancer, where the base-modified RNA sequence contains base modification and codes for a protein - recombinant protein produced by vector mediated gene expression in host cell, useful as vaccine for prevention of cancer, autoimmune disease and infectious disease

AUTHOR: HOERR I; VON DER MUELBE F

PATENT ASSIGNEE: CUREVAC GMBH 2008

PATENT NUMBER: WO 200852770 PATENT DATE: 20080508 WPI ACCESSION NO.:

2008- L50656 (200867)

PRIORITY APPLIC. NO.: DE 10051516 APPLIC. DATE: 20061031

NATIONAL APPLIC. NO.: WO 2007EP9469 APPLIC. DATE: 20071031

LANGUAGE: English

... ABSTRACT: P1205); cytokine-containing liposomes; dimethyldioctadecyl ammonium bromide (DDA); dehydroepiandrosterone (DHEA); DMPC (dimyristoylphosphatidylcholine); dimyristoylphosphatidylglycerol (DMPG); DOG/alum complex (deoxycholic acid sodium salt); Freund's complete adjuvant; Freund's incomplete adjuvant; gamma inulin; Gerbu...

... acetylmuramyl-L-alanyl-D-glutamine (GMDP), (ii) dimethyldioctadecyl ammonium chloride (DDA), (iii) zinc-L-proline salt complex (ZnPro-8); granulocyte macrophage-colony stimulating factor (GM-CSF); N-acetylglucosaminyl-(b1-4)-N-acetylmuramyl...

... PODDS(RTM proteinoid microspheres); polyethylene carbamate derivatives; poly-rA: poly-rU (polyadenylic acid polyuridylic acid complex);

10562866.txt
polysorbate 80 (Tween 80); protein cochleates; STIMULON(RM QS-21);
Quil-A (Quil-A saponin); S-28463
(4-amino-otectadimethyl-2-ethoxymethyl-1H-imidazo(4,5-c)-quinoline-1...

16/3, K/40 (Item 5 from file: 357)
DI ALOG(R) File 357: Derwent Biotech Res.
(c) 2009 Thomson Reuters. All rights reserved.

0450154 DBR Accession No.: 2008-08663 PATENT
Use of lipid containing particles comprising at least one lipid and at
least one saponin for the preparation of a pharmaceutical for the
treatment of cancer - pharmaceutical composition comprising liposome,
useful in treatment of cancer

AUTHOR: HU K; MOREIN B

PATENT ASSIGNEE: DUECOM 2008

PATENT NUMBER: WO 200863129 PATENT DATE: 20080529 WPI ACCESSION NO.:
2008-J04888 (200851)

PRIORITY APPLIC. NO.: US 866445 APPLIC. DATE: 20061120

NATIONAL APPLIC. NO.: WO 2007SE50878 APPLIC. DATE: 20071120

LANGUAGE: English

Use of lipid containing particles comprising at least one lipid and at
least one saponin for the preparation of a pharmaceutical for the
treatment of cancer - pharmaceutical composition comprising liposome...
... ABSTRACT: NOVELTY - Use of lipid containing particles comprising at
least one lipid and at least one saponin for the preparation of a
pharmaceutical for the treatment of cancer. DETAILED DESCRIPTION -
INDEPENDENT CLAIMS...

... cancer where a lipid containing particle comprising at least one lipid
and at least one saponin is administered to an individual cancer
treatment; and (2) kit of parts comprising at least two parts, where
one part comprises lipid containing particles comprising at least one
saponin fraction which is hydrophobic having a killing effect on
cancer cells; and the other part comprises lipid containing particles
having at least one saponin fraction which is hydrophilic,
stimulating and modulating the immune response such as antibody
production and...

... sapogenins and prosapogenins with one or more sugar moieties, where the
glycoside is a crude saponin fraction from Quillaja
Saponaria Molina or its sub fraction, and where the saponin is
chosen from fraction A, fraction B, fraction C, fractions QA 1-22 of
Quillaja Saponaria Molina, Spicoides, or QVAC. The saponin
fraction is hydrophilic, such as fractions that do not contain fatty
acids e.g. fraction A, Quil 4-15, stimulating and modulating the
immune response such as antibody production and cell mediated immunity.
The saponin fraction is hydrophobic such as fractions that do
contain fatty acids e.g. in the 4-position of the saponins such as
fraction C and B of Quil A or fractions from the region between
fractions A and B, fractions QA 15-21 of Quillaja Saponaria
Molina having a killing effect on cancer cells; where the lipid
containing particles further also comprise hydrophilic saponins. The
lipid containing particles contain at least two different saponin
fractions in one and the same lipid containing particle. The lipid
containing particles contain at least two different saponin
fractions, where one of the at least two different saponin
fractions is complex bound in one lipid containing particle and
the other one (the other ones) of the at least two different
saponin fractions is (are) complex bound in another (other)
physical different lipid containing particle(s). The different saponins
are hydrophilic and hydrophobic saponins, where mixtures of lipid

10562866.txt

containing particles comprising at least one hydrophilic saponin, e.g. fraction A from Quil A is used together with lipid containing particles comprising at least one hydrophobic saponin e.g. fraction C from Quil A for a synergistic anticancer effect. The lipid containing particles comprise cancer antigens integrated into

... mustard or nitrosourea alkylating agents, anti-tumor anthracycline derivatives, trastuzumab and anti-tumor podophyllotoxin derivatives, Quil A, or their sub fragments. The adjuvants integrated into the particles, coupled on to the...

... from liposomes, iscom and/or iscom matrix and posintros, where iscoms comprising at least one saponin, at least one lipid and at least one type of antigen substance are used, where iscom matrix comprising at least one saponin and at least one lipid is used. ACTIVITY - Cytostatic. No biological data given. MECHANISM OF...

16/3, K/41 (Item 6 from file: 357)
DIALOG(R) File 357: Derwent Biotech Res.
(c) 2009 Thomson Reuters. All rights reserved.

0429983 DBR Accession No.: 2007-16290 PATENT
Inducing an immune response in a mammal against autologous high mobility group box 1 (HMGB1) for treating or preventing e.g., cancer by effecting uptake and processing of a modified HMGB1 polypeptide by antigen presenting cells - human high mobility group box-1 protein and expression virus vector for use in disease prevention and gene therapy
AUTHOR: BRATT T; DEGAN F D; NIELSEN K B; VOLDORGB B; HOLMBERG J
PATENT ASSIGNEE: PHARMEXA AS 2007
PATENT NUMBER: WO 200754090 PATENT DATE: 20070518 WPI ACCESSION NO.: 2007-468796 (200745)
PRIORITY APPLIC. NO.: US 734747 APPLIC. DATE: 20051109
NATIONAL APPLIC. NO.: WO 2006DK614 APPLIC. DATE: 20061108
LANGUAGE: English

... ABSTRACT: cytokine, and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle; DDA; aluminum adjuvants; DNA adjuvants; gamma-inulin; or an encapsulating

... PEG, starch, mannan, and mannose; a plastic polymer; or latex such as latex beads. The saponin is Quilaja saponaria saponin, Quil A or QS21. The particle comprises latex or dextran. The method includes at least one...

16/3, K/42 (Item 7 from file: 357)
DIALOG(R) File 357: Derwent Biotech Res.
(c) 2009 Thomson Reuters. All rights reserved.

0411127 DBR Accession No.: 2006-24623 PATENT
Inducing an immune response against autologous Epidermal Growth Factor Receptor (EGFR) comprises effecting uptake and processing by antigen presenting cells (APCs) in a subject of a modified EGFR polypeptide - involving vector plasmid, phage, cosmid, chromosome or virus-mediated gene transfer and expression in host cell for use in gene therapy
AUTHOR: STEINAA L; RENARD V
PATENT ASSIGNEE: PHARMEXA AS 2006
PATENT NUMBER: WO 2006102901 PATENT DATE: 20061005 WPI ACCESSION NO.: 2006-670377 (200669)
PRIORITY APPLIC. NO.: US 667441 APPLIC. DATE: 20050331

NATIONAL APPLIC. NO.: WO 2006DK184 APPLIC. DATE: 20060330
 LANGUAGE: English

... ABSTRACT: foreign TH epitopes are selected from a natural TH epitope or an artificial major histocompatibility complex (MHC)-II binding peptide sequence. The natural T-cell epitope is selected from a Tetanus ...

... cytokine, and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; y-inulin; or an encapsulating...

... starch, mannan, and mannose; a plastic polymer; and latex such as latex beads, where the saponin is Quillaja saponaria saponin, Quil A, and QS21, and where the particle comprises latex or dextran. It includes 1-12...

16/3, K/43 (Item 8 from file: 357)
 DIALOG(R) File 357: Derwent Biotech Res.
 (c) 2009 Thomson Reuters. All rights reserved.

0320597 DBR Accession No.: 2003-21737 PATENT
 Inducing an immune response in humans against autologous carcinoembryonic antigen (CEA) comprises administering a modified CEA polypeptide, a nucleic acid encoding the polypeptide, or a microorganism expressing the polypeptide - vector-mediated gene transfer and expression in host cell for recombinant vaccine and cancer therapy

AUTHOR: KLYSNER S; VOLDORGB B
 PATENT ASSIGNEE: PHARMEXA AS 2003
 PATENT NUMBER: WO 200359379 PATENT DATE: 20030724 WPI ACCESSION NO.: 2003-587260 (200355)
 PRIORITY APPLIC. NO.: US 350047 APPLIC. DATE: 20020117
 NATIONAL APPLIC. NO.: WO 2003DK31 APPLIC. DATE: 20030117
 LANGUAGE: English

... ABSTRACT: CEA-derived CTL epitope is presented by the APC in association with a Major Histocompatibility Complex (MHC) Class I molecule on the surface of the APC and/or where the first...

... cytokine and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; gamma-inulin; and an encapsulating...

... PEG, starch, mannan, and mannose; a plastic polymer and latex such as latex beads. The saponin is Quillaja saponaria saponin, Quil A or QS21. The particle comprises latex or dextran. The method also comprises administering to...

16/3, K/44 (Item 9 from file: 357)
 DIALOG(R) File 357: Derwent Biotech Res.
 (c) 2009 Thomson Reuters. All rights reserved.

0314119 DBR Accession No.: 2003-15259 PATENT
 Novel stable HIV-1 pre-fusion envelope glycoprotein trimeric complex in which each monomeric unit of the complex comprises HIV-1 gp120 and HIV-1 gp41, useful for eliciting immune response in subject against HIV-1 - HIV virus glycoprotein production by virus vector expression in host cell for use in recombinant vaccine and therapy

AUTHOR: MOORE J P; BINLEY J M; LU M; OLSON W C; SCHULKE N; GARDNER J;

MADDON P J; SANDERS R
 PATENT ASSIGNEE: PROGENICS PHARM INC; CORNELL RES FOUND INC 2003
 PATENT NUMBER: WO 200322869 PATENT DATE: 20030320 WPI ACCESSION NO.:
 2003-371744 (200335)
 PRIORITY APPLIC. NO.: US 370410 APPLIC. DATE: 20020405
 NATIONAL APPLIC. NO.: WO 2002US28331 APPLIC. DATE: 20020906
 LANGUAGE: English

Novel stable HIV-1 pre-fusion envelope glycoprotein trimeric complex
 in which each monomeric unit of the complex comprises HIV-1 gp120
 and HIV-1 gp41, useful for eliciting immune response in subject...
 ABSTRACT: DERWENT ABSTRACT: NOVELTY - A stable HIV-1 pre-fusion envelope
 glycoprotein trimeric complex (I), where each monomeric unit of
 (I) comprising HIV-1 gp120 and HIV-1 gp41...

... (II) by contacting a particle with a stable HIV-1 pre-fusion envelope
 glycoprotein trimeric complex under conditions permitting the
 complex to become operably affixed to the particle, or by
 contacting a particle having an agent which binds to a stable HIV-1
 pre-fusion envelope glycoprotein trimeric complex under
 conditions permitting the complex to bind to the agent, thus
 permitting the complex to become operably affixed to the
 particle. BIOTECHNOLOGY - Preparation: (II) is produced by growing (VI)
 and recovering (II) (claimed). Preferred Complex: In (I), the
 gp41 and gp120 of each monomeric unit are produced by proteolytic
 cleavage...

... which forms the trimer interface in the post-fusion 6-helix bundle of
 the trimeric complex. The amino acid mutation in (I) is I559P.
 The mutated furin recognition sequence has the...

... Lys-Arg or Arg-Arg-Arg-Arg-Arg-Arg. Preferred Composition: In (III), the
 trimeric complex is operably affixed to the particle through an
 agent which is operably affixed to the...

... 10, MG or their combination. The adjuvant is selected from alum,
 Freund's incomplete adjuvant, saponin, Quil A, QS-21, Ribi
 Detox, monophosphoryl lipid A, CpG oligonucleotide, CRL-1005, L-121 or

DESCRIBTORS: stable HIV virus pre-fusion envelope glycoprotein trimeric
 complex, HIV virus-1, gp120, gp41, cosmid, lambda phage, yeast
 artificial chromosome, alpha virus vector-mediated...

16/3, K/45 (Item 10 from file: 357)
 DIALOG(R) File 357: Derwent Biotech Res.
 (c) 2009 Thomson Reuters. All rights reserved.

0070976 DBR Accession No.: 88-01324 PATENT
 Complex immunogen for use in vaccines against e.g. hepatitis B virus
 - comprising a core structure of a saponin derivative and several
 copies of 1 or more distinct synthetic or natural peptides; cloning
 etc.
 PATENT ASSIGNEE: N. Y. Blood-Center; Calif. Inst. Technol. 1987
 PATENT NUMBER: EP 244719 PATENT DATE: 871111 WPI ACCESSION NO.: 87-314944
 (8745)
 PRIORITY APPLIC. NO.: US 856909 APPLIC. DATE: 860428
 NATIONAL APPLIC. NO.: EP 87106051 APPLIC. DATE: 870425
 LANGUAGE: English

Complex immunogen for use in vaccines against e.g. hepatitis B virus
 - comprising a core structure of a saponin derivative and several
 copies of 1 or more distinct synthetic or natural peptides; cloning

et c.

ABSTRACT: A complex immunogen comprises a core structure and several copies of 1 or more distinct synthetic peptides (I) covalently linked to the core structure which comprises a saponin derivative (II) and a 7-24C organic compound (III) or a hydrophobic peptide (IV) having

... moieties selected from COOH, CHO, NH₂ and SH. Preferably (III) is octadecanethiol and (II) is Quil A. The complexes overcome potential problems inherent in single-peptide immunogens, i.e. insufficient T...

DESCRIPTORS: hepatitis B virus et c. complex immunogen peptide vaccine prep., peptide cloning et c.

16/3, K/46 (Item 11 from file: 357)
 DI ALOG(R) File 357: Derwent Biotech Res.
 (c) 2009 Thomson Reuters. All rts. reserv.

0066892 DBR Accession No.: 87-11240 PATENT
 Preparation of immunogenic complexes for use in vaccines - iscom preparation using e.g. measles virus
 PATENT ASSIGNEE: Ned. Min. Health-Public-Health-Cult. 1987
 PATENT NUMBER: EP 231039 PATENT DATE: 870805 WPI ACCESSION NO.: 87-215249 (8731)
 PRIORITY APPLIC. NO.: NL 8666 APPLIC. DATE: 860114
 NATIONAL APPLIC. NO.: EP 87200035 APPLIC. DATE: 870113
 LANGUAGE: English

... ABSTRACT: or peptide with a solution containing a detergent, a sterol, and a glycoside, preferably a saponin, with hydrophobic and hydrophilic regions in at least the critical micelle forming concentration, removing the...

... 350 ug each of phosphatidylethanolamine and cholesterol. After 1 hr at RT, 1.7 mg Quil A saponin from Quilaja saponaria was added and the mixture dialyzed against 10 mM Tris-HCl. The iscoms were

DESCRIPTORS: new iscom immunogenic complex comp., appl. as vaccine against e.g. measles virus

16/3, K/47 (Item 1 from file: 149)
 DI ALOG(R) File 149: TGG Health&Wellness DB(SM)
 (c) 2009 Gale/Cengage. All rts. reserv.

01489919 SUPPLIER NUMBER: 15828334 (USE FORMAT 7 OR 9 FOR FULL TEXT)
 Vaccine technologies: view to the future. (Cover Story)
 Rabinovich, N. Regina; McInnes, Pamela; Klein, David L.; Hall, B. Fenton
 Science, v265, n5177, p1401(4)
 Sept 2, 1994
 DOCUMENT TYPE: Cover Story PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075
 LANGUAGE: English RECORD TYPE: Fulltext; Abstract
 TARGET AUDIENCE: Academic
 WORD COUNT: 4497 LINE COUNT: 00384

... tripeptide MTPPE], the Ribiformulation (containing monophosphoryl lipid A and mycobacterial cell walls), and the saponin derivatives, especially the Cambridge Biotech QS21. The Ribiformulation has been clinically tested with a... immunostimulatory complexes). These structures are generated by mixing antigen with a biocompatible detergent and the complex adjuvant Quil A. The ISCOM self-assembles into stable 35-nm cage-like structures held together by the hydrophobic interactions

between the matrix (Quil A), added lipids, and the antigen. ISCOMs containing viral membrane proteins have been tested in...
...perhaps through the delivery of antigen directly to the cytosol for presentation with major histocompatibility complex (MHC) class I molecules (19). Cytosolic antigen delivery by membrane-active adjuvants mimics the antigen...

...during viral infection or after immunization with live attenuated vaccines. Concerns about the safety of Quil A must be resolved before ISCOMs can be administered to humans.

Protein cochleates, which are...linked to protein carriers (including tetanus or diphtheria toxoids) or to an outer membrane protein complex of *Neisseria meningitidis* group B (22). Conjugate vaccines are relatively expensive to produce, so an...

16/3, K/48 (Item 2 from file: 149)
DI ALOG(R) File 149: TGG Health&Wellness DB(SM)
(c) 2009 Gale/Cengage. All rts. reserv.

01361226 SUPPLIER NUMBER: 12308106 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Galactose oxidation in the design of immunogenic vaccines.
Zheng, Biao; Brett, Sara J.; Tite, John P.; Lifely, M Robert; Brodie, Thomas A.; Rhodes, John
Science, v256, n5063, p1560(4)
June 12,
1992
PUBLICATION FORMAT: Magazine/Journal ISSN: 0036-8075 LANGUAGE: English
RECORD TYPE: Fulltext TARGET AUDIENCE: Academic
WORD COUNT: 2337 LINE COUNT: 00195

... In addition to the recognition that takes place between the T cell receptor and the complex of Ag and major histocompatibility complex (MHC) class II molecule, essential accessory interactions occur at the macromolecular level [5] At the...

...merozoite surface antigens[13] (recombinant baculovirus-derived PMMSA), NAGO was superior to both alum and saponin and comparable to FCA (Fig. 2F).

NAGO was effective as an adjuvant in the induction of secondary antibody responses to HIV-gp120 (CHO), producing titers comparable to FCA and saponin, whereas alum was ineffective. Reciprocal [log.sub.10] titers in groups of four CBA mice...

...incomplete adjuvant (FIA)] were as follows: FCA, 4.4, 4.4, 4.4, 2.6; saponin, 4.4, 4.4, 4.4, 3.2; NAGO, 4.4, 3.8, 2.6...unimportant, and this is what we found.

NAGO was generally more effective than FCA and saponin in priming T cells, but this was not fully reflected in antibody responses, where NAGO...

...for this strain[11,16], NAGO was effective as an adjuvant, comparable to FCA and saponin in priming for CTL, or even surpassing these when in vitro boosting was with peptide...

...before injection): FCA (Difco): 50 [mu] of Ag solution emulsified in 50 [mu] of FCA; saponin (Quil A, Superfos, Denmark): 50 [mu] in 100[mu] of PBS containing AG: alum (Wellcome, Beckenham...

16/3, K/49 (Item 1 from file: 444)
DI ALOG(R) File 444: New England Journal of Med.
(c) 2009 Mass. Med. Soc. All rts. reserv.

00115110

Copyright 1995 by the Massachusetts Medical Society

Drug Therapy: Candidate AIDS Vaccines (Review Article)

Graham Barney S.; Wight, Peter F.
The New England Journal of Medicine
Nov 16, 1995; 333 (20), pp 1331-1339
LINE COUNT: 00487 WORD COUNT: 06722

TEXT

...will be the chief effector mechanism it must take into account class I major histocompatibility complex (MHC) restriction. The vaccine will have to incorporate a spectrum of epitopes broad enough to...mammalian cell lines. Adjuvants formulated with gp120 have included alum QS21 (a purified triterpene glycoside saponin) with or without alum MF59 (a squalene oil-in-water emulsion) with or without MTP...spectrum of strains of HIV-1. This is a challenging list of qualities, given the complex biological features of HIV-1 infection. Conquering this problem will require the cooperation of many...

CITED REFERENCES

...369-88.

71. Mowat AMCI, Donachie AM, Reid G, Jarrett O. Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are...

...84. Zagury JF, Bernard J, Achour A, et al. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein...

16/3, K/50 (Item 1 from file: 32)
DI ALOG(R) File 32: METADEX
(c) 2009 CSA. All rights reserved.

0002437559 I P ACCESSION NO: 200807-71-0898055
Immunogenic complexes

Kersten, Gideon F A; Spijkstra, Arjan; Van Der Werken, Gerrit; Beuvery, Eduard C

, USA

PUBLISHER URL:

<http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=/netah/PTO/sear ch-adv. htm&r=1&p=1&f=G&l=50&d=PTXT&S1=5620690. PN.&OS=pn/5620690&RS=PN/5620690>

DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English
FILE SEGMENT: Metadex

ABSTRACT:

... particular three-dimensional iscoms, which immunogenic complexes are composed of at least one sterol, one saponin and, in the case of iscoms, also a phospholipid and also, optionally, at least one antigen generating an immune reaction. The saponin used is at least one of the fractions which are derived from Quil A by means of hydrophobic interaction chromatography and have the designations QA 1 to QA 23, as is shown in the figure by the numerals 1 to 23. Preferably, the saponin

used is one or more of the fractions derived from Quil A having the designations QA 3, QA 17 and QA 23. As well as relating to the immunogenic complex, the invention also relates to the specific method of preparation of the relevant Quil A fractions, to vaccines which contain such immunogenic complexes and to kits which contain, on the one hand, an (empty) immunogenic complex and, on the other hand, one or more antigenic proteins or peptides having a hydrophobic...